# IMPORTS:
import streamlit as st
import pandas as pd
from transformers import AutoTokenizer, AutoModel
import torch
from sklearn.metrics.pairwise import cosine_similarity

# GLOBAL VARIABLES:

# FUNCTIONS:
@st.cache()
def get_sentences_dataset():
    data = [
        [2019, "We found that venetoclax and voreloxin synergistically induced apoptosis in multiple AML cell lines."],
        [2010, "Anthracyclines like daunorubicin (daunorubicin) are important drugs in the treatment of AML (AML)."],
        [2004, "Recent resurgence in the use of arsenictrioxide is related to its high efficacy in AML (APL)."],
        [2019, "Adding pioglitazone to cytarabine and daunorubicin increased the remission rate in AML patients compared to control subjects."],
        [2017, "Furthermore, we explored the in vivo activity of quinacrine in combination with the widely used AML agent cytarabine."],
        [2015, "Finally, Msi2 silencing in AML cells also enhanced their chemosensitivity to daunorubicin."],
        [2017, "Together with anthracyclines, cytarabine forms the backbone of AML treatment for children and adults."],
        [2011, "It is well recognized that arsenictrioxide (arsenictrioxide) is an efficacious agent for the treatment of AML (APL)."],
        [2016, "Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type AML models."],
        [2010, "arsenictrioxide (arsenictrioxide) is a widely used drug for AML (APL)."],
        [2018, "Population Pharmacokinetics of Volasertib Administered in Patients with AML as a Single Agent or in Combination with Cytarabine."],
        [2016, "Pre-treatment with DAC restores cellular sensitivity in cytarabine-resistant AML cells."],
        [1995, "The effect of haemopoietic growth factors on the cell cycle of AML progenitors and their sensitivity to cytarabine in vitro."],
        [2003, "This study was performed to investigate the effects of dexamethasone on AML (AML) cells."],
        [2017, "Synergistic antileukemic interactions between AZ20 and cytarabine were confirmed in primary AML patient samples."],
        [2014, "Retinoic acid synergizes arsenictrioxide-mediated cytotoxicity by precluding Nrf2 activity in AML cells."],
        [2014, "A total of 51 patients with AML (AML) induction failure were given elacytarabine-idarubicin as a second induction course."],
        [1985, "Treatment of AML with a daunorubicin cytarabine thioguanine regimen without maintenance therapy."],
        [2022, "Impact of Venetoclax and azacitidine in Treatment-Naïve Patients with AML and IDH1/2 Mutations."],
        [2002, "arsenictrioxide (arsenictrioxide) is a novel agent to treat AML (APL)."],
        [2020, "Slower degradation rate of cytarabine in blood samples from AML by comparison with control samples."],
        [2017, "PP2A inhibition from LB100 therapy enhances daunorubicin cytotoxicity in secondary AML via miR-181b-1 upregulation."],
        [2013, "Effects of azacitidine on matrix metalloproteinase-9 in AML and myelodysplasia."],
        [2021, "Midostaurin is an FMS-like dl-tyrosine kinase 3 receptor (FLT3) inhibitor that provides renewed hope for treating AML (AML)."],
        [2013, "azacitidine is a hypomethylating agent with recognized efficacy in high risk myelodysplasia and AML in the elderly."],
        [2021, "JAK-STAT inhibitor as a potential therapeutic opportunity in AML patients resistant to cytarabine and epigenetic therapy."],
        [2009, "The Prognostic Impact of K-RAS Mutations in Adult AML Patients Treated with High Dose Cytarabine."],
        [2020, "Venetoclax combined with 5 + 2 induction chemotherapy was safe and tolerable in fit older patients with AML."],
        [2000, "All patients with relapsed or persistent AML had been pretreated with IDA and cytarabine."],
        [2018, "Midostaurin has been shown to improve outcomes in FLT3-mutated AML in the frontline setting."],
        [2022, "Gilteritinib is approved for the treatment of relapsed/refractory (R/R) AML (AML) with an FLT3-mutation (FLT3mut+ )."],
        [2001, "Arsenic oxide (arsenictrioxide) has recently been reported to induce remission in a high percentage of patients with AML (APL)."],
        [2022, "Resistance to cytarabine is a key problem in the treatment of AML (AML)."],
        [2006, "MEK1 inhibition sensitizes primary AML to arsenictrioxide-induced apoptosis."],
        [2020, "arsenictrioxide), we revived an oral formulation of pure arsenictrioxide in 1998 for the treatment of AML (APL)."],
        [2021, "The standard treatment for pediatric AML currently consists in a combination of cytarabine (cytarabine) and antracycline."],
        [2004, "The impressive activity of arsenictrioxide in AML (APL) has renewed the interest in this old compound."],
        [2022, "Characterisation of infections in patients with AML receiving venetoclax and a hypomethylating agent."],
        [1995, "Low-dose cytarabine in patients with AML not eligible for standard chemotherapy."],
        [2016, "arsenictrioxide (arsenictrioxide) is an efficient drug for the treatment of the patients with AML (APL)."],
        [2015, "The efficacy and pharmacodynamics of MLN4924/cytarabine were assessed in an AML xenograft model."],
        [2011, "Outcome of therapy-related AML with or without arsenictrioxide as a component of frontline therapy."],
        [2022, "However, resistance eventually develops, decreasing the efficacy of cytarabine in AML patients."],
        [2013, "Cytarabine arabinoside (cytarabine) is the key agent for treating AML (AML)."],
        [2009, "The mainstay of AML chemotherapy is the nucleoside analog cytarabine (cytarabine)."],
        [2021, "NOXA-mediated degradation of MCL1 and BCL2L1 causes apoptosis of daunorubicin-treated human AML cells."],
        [2021, "In cytarabine-adapted AML cells, increased SAMHD1 and reduced DCK levels contributed to cytarabine and CNDAC resistance."],
        [2013, "arsenictrioxide has been successfully used as a therapeutic in the treatment of AML (APL)."],
        [2007, "arsenictrioxide (As(2)O(3)) is highly efficacious for AML (APL)."],
        [2017, "High-dose cytarabine is recommended for re-induction chemotherapy in patients less than 60 years of age with AML."],
        [2009, "Patients diagnosed with AML are often treated with a combination of daunorubicin and cytarabine (cytarabine)."],
        [2021, "In addition, co-incubation with PMPs protected THP-1 and primary AML cells against daunorubicin-induced cell death."],
        [2021, "Mechanistically, synergistic anti-tumor effect of cytarabine/)Brusatol in AML cells is mediated by attenuating Nrf2 expression."],
        [2022, "Surface-modified vacuole-based daunorubicin delivery system for AML (AML) and their selective therapeutics."],
        [2019, "azacitidine therapy was utilised in ten eligible patients, while four received induction chemotherapy for AML."],
        [2017, "Before the introduction of anthracyclines and cytarabine in the 1960s, AML (AML) was considered a fatal disease."],
        [2020, "arsenictrioxide (arsenictrioxide) an evident effect in the treatment of AML and other malignant tumors in recent years."],
        [2021, "Single-center experience with venetoclax combinations in patients with newly diagnosed and relapsed AML evolving from MPNs."],
        [2003, "vincristine (vincristine) is an effective drug against acute lymphoblastic leukemia (ALL), many solid tumors, but not AML."],
        [2009, "Intensive induction chemotherapy with regimen containing intermediate dose cytarabine in the treatment of de novo AML."],
        [2007, "arsenictrioxide (arsenictrioxide) is highly efficacious in AML (APL)."],
        [2020, "Daunorubicin is a chemotherapy medication used to treat cancer, specifically for AML."],
        [2017, "Autophagy is an important event for low-dose cytarabine treatment in AML cells."],
        [2015, "arsenictrioxide (arsenictrioxide) is one of the most effective therapeutic agents used for patients with AML (APL)."],
        [2015, "The combination of midostaurin and AZA is an effective and safe regimen in patients with AML and high-risk MDS."],
        [2017, "Idarubicin (IDR), cytarabine (cytarabine), and tamibarotene (Am80) are effective for treatment of AML (AML)."],
        [2012, "Allogeneic stem cell transplantation for advanced AML in the ATRA and arsenictrioxide era."],
        [2018, "Clofarabine and cytarabine (Clo + Ara-C) combinations have efficacy in treatment of AML (AML)."],
        [2018, "arsenictrioxide (As₂O₃), a traditional remedy in Chinese medicine, has been used in AML (APL) research and clinical treatment."],
        [2011, "The prognostic impact of K-RAS mutations in adult AML patients treated with high-dose cytarabine."],
        [2017, "We describe 17 children and adolescents with relapsed/refractory AML who received clofarabine, cyclophosphamide, and etoposide."],
        [2012, "Pharmacologic inhibition of WEE1 in AML cell lines and primary cells is synergistic with cytarabine."],
        [2009, "Effective treatment of AML with all-trans-retinoic acid, arsenictrioxide, and gemtuzumab-ozogamicin."],
        [2006, "arsenictrioxide is now considered the standard agent in treatment of refractory cases of AML (APL)."],
        [2021, "The standard chemotherapy for AML (AML) is usually composed of anthracyclines and cytarabine."],
        [2021, "A Relapsing Meningeal AML FLT3-ITD+ Responding to Gilteritinib."],
        [2014, "In the past decade, the therapeutic potential of arsenictrioxide (arsenictrioxide) in the treatment of AML (APL) was recognized."],
        [2019, "Both lenalidomide (LEN) and azacitidine (azacitidine) possess significant antitumor activity effect in AML."],
        [2002, "We conclude that ATRA in combination with Ida and cytarabine can be administered safely to high-risk AML patients."],
        [1995, "Clonogenic data from fresh AML LDMCs not pretreated with growth factors demonstrated a heterogenous response to cytarabine."],
        [2017, "The FDA has approved the small-molecule inhibitor midostaurin in combination with chemotherapy to treat AML."],
        [2020, "FHL1-targeted intervention enhances the sensitivity of AML cells to cytarabine."],
        [2022, "Effect of Chemotherapy Cytarabine and AML on the Development of Spermatogenesis at the Adult Age of Immature Treated Mice."],
        [1996, "Haemopoietic growth factors, the cell cycle of AML progenitors and sensitivity to cytarabine."],
        [2013, "zidovudine hinders arsenictrioxide-induced apoptosis in AML cells by induction of p21 and attenuation of G2/M arrest."],
        [2011, "CD34+ AML cells are 10-15-fold more resistant to daunorubicin (daunorubicin) than CD34- AML cells."],
        [2020, "Isavuconazole Therapy of Disseminated and Encephalic Saprochaete Capitata Infection in an AML Patient Treated with Midostaurin."],
        [2001, "Successful treatment of hepatosplenic candidiasis in an elderly patient with AML using liposomaldaunorubicin and fluconazole."],
        [2017, "Mechanisms responsible for the synergistic antileukemic interactions between ATR inhibition and cytarabine in AML cells."],
        [1987, "Low-dose cytarabine (LD-Ara C) treatment in dysmyelopoietic syndromes (DMPS) and AML (AML)."],
        [2020, "Cladribine, cytarabine, and idarubicin in relapsed AML is feasible and induces good response rates."],
        [2011, "QTc prolongation is associated with arsenictrioxide (arsenictrioxide) treatment of AML (APL)."],
        [1996, "GM-CSF administered during induction treatment of AML with a DNR/cytarabine combination did not provide any clinical benefit."],
        [2021, "We discovered that venetoclax directly activated T cells to increase their cytotoxicity against AML (AML) in vitro and in vivo."],
        [2019, "Venetoclax is approved for older untreated AML (AML) patients."],
        [2016, "EZH2 mediates arsenictrioxide-induced apoptosis in AML cell lines through the Wnt signaling pathway."],
        [2006, "Effect of gemtuzumab-ozogamicin on AML blast cells in vitro, as a single agent and combined with other cytotoxic cells."],
        [2016, "STAT5 gene polymorphisms are associated with the response of AML patients to cytarabine-based chemotherapy."],
        [1974, "The use of a combination of daunorubicin and cytarabine in the treatment of AML in a district general hospital is described."],
        [2009, "Effect of laromustine (VNP40101M) on AML blast cells in vitro as a single agent and combined with cytarabine and daunorubicin."],
        [2019, "Ivosidenib is an approved drug for relapsed or refractory IDH1 mutant AML patients."],
        [1989, "23 adult patients with refractory or relapsed AML (AML) received salvage chemotherapy with mitoxantrone and etoposide."],
        [2015, "arsenictrioxide (As2 O3 ) is commonly used to treat AML and solid tumors."],
        [2013, "AKT signaling as a novel factor associated with in vitro resistance of human AML to gemtuzumab-ozogamicin."],
        [2013, "arsenictrioxide (arsenictrioxide) induces disease remission in AML (APL) patients, but not in non-APL AML (AML) patients."],
        [2010, "arsenictrioxide (arsenictrioxide) is an effective therapeutic agent for AML (APL) and other hematopoietic malignancies."],
        [2020, "TRIM31 promotes AML progression and sensitivity to daunorubicin through the Wnt/β-catenin signaling."],
        [2018, "Arsenic speciation in hair and nails of AML (APL) patients undergoing arsenictrioxide treatment."],
        [2020, "Encapsulation of daunorubicin into Saccharomyces cerevisiae-derived lysosome as drug delivery vehicles for AML (AML) treatment."],
        [2015, "Cytarabine arabinoside (cytarabine) is the most important agent for treating AML (AML)."],
        [2017, "We showed that BMSCs secrete soluble factors that protect AML cells from cytarabine induced cytotoxicity."],
        [2019, "Elevated VMP1 expression in AML amplifies autophagy and is protective against venetoclax-induced apoptosis."],
        [2018, "Venetoclax (venetoclax) targets BCL-2 and has shown promising efficacy in AML but over-expression of MCL-1 can cause resistance."],
        [2001, "Treatment of AML cells with cytarabine and imatinibmesylate showed synergistic effect at low concentrations."],
        [2021, "HDAC8 promotes daunorubicin resistance of human AML cells via regulation of IL-6 and IL-8."],
        [2013, "Daunorubicin has historically been considered the anthracycline of choice at many cancer centers for the treatment of AML (AML)."],
        [2001, "arsenictrioxide (arsenictrioxide) effectively induces clinical remission via apoptosis in relapsed AML (APL)."],
        [2011, "With the introduction of all-trans retinoic acid (ATRA) and arsenictrioxide, AML (APL) has become a highly curable malignancy."],
        [2015, "Musashi-2 Silencing Exerts Potent Activity against AML and Enhances Chemosensitivity to Daunorubicin."],
        [2017, "The cytostatic deoxycytidine analog cytarabine (cytarabine) is the most active agent available against AML (AML)."],
        [2022, "Long-term remission of extramedullary cutaneous relapse of AML (leukemia cutis) treated with decitabine-venetoclax."],
        [2019, "arsenictrioxide (arsenictrioxide) has been used clinically for the treatment of AML and some solid tumors."],
        [2012, "Resistance to gemtuzumab-ozogamicin (gemtuzumab-ozogamicin) hampers the effective treatment of refractory AML (AML)."],
        [2020, "Cytarabine stability is higher in AML than in CTRL samples."],
        [2018, "Chloroquine exerts antitumor effects on NB4 AML cells and functions synergistically with arsenictrioxide."],
        [2021, "Vitamin C (Vit C) is reported to enhance the antineoplastic action of azacitidine-CdR on AML cells."],
        [2018, "Downregulation of ROS1 enhances the therapeutic efficacy of arsenictrioxide in AML cell lines."],
        [2012, "CDA RNA expression as well as cytarabine IC₅₀ showed wide variation in AML samples and normal controls."],
        [1996, "Clinical and laboratory studies of 2'-chloro-2'-deoxyadenosine +/- cytarabine for relapsed or refractory AML in adults."],
        [2008, "Low dose interleukin-2 following intensification therapy with high dose cytarabine for AML in first complete remission."],
        [2016, "Synergistic anti-leukemic interactions between venetoclax and panobinostat in AML ex vivo."],
        [2016, "Parenteral arsenictrioxide (arsenictrioxide) has been firmly established as a standard therapy for AML (APL)."],
        [2006, "Molecular response in two children with relapsed AML treated with a combination of gemtuzumab-ozogamicin and cytarabine."],
        [2021, "Enhanced cytarabine-induced killing in OGG1-deficient AML cells."],
        [2015, "Upregulation of microRNA-126-5p is associated with drug resistance to cytarabine and poor prognosis in AML patients."],
        [2005, "arsenictrioxide (As(2)O(3)) is effective against AML and has potential as a novel treatment against malignant solid tumors."],
        [2020, "c-Myc Inhibition Using 10058-F4 Increased the Sensitivity of AML Cells to arsenictrioxide Via Blunting PI3K/NF-κB Axis."],
        [2013, "cytarabine (cytarabine or cytarabine) has been one of the cornerstones of treatment of AML since its approval in 1969."],
        [2021, "In addition, compound 31 combined with idarubicin synergistically inhibited the proliferation of AML cells."],
        [2002, "arsenictrioxide is highly effective in the treatment of AML (APL)."],
        [2019, "The combination of cytarabine and an anthracycline has been the standard of care for the induction of remission in AML (AML)."],
        [1991, "The pharmacokinetics of thioguanine were studied in 10 patients with AML treated with 25-100 mg/m(2) orally."],
        [2005, "Intrinsically activated Ras seems to increase sensitivity of the AML blast to high-dose cytarabine therapy."],
        [2018, "Heteronemin, a marine natural product, sensitizes AML cells towards cytarabine chemotherapy by regulating farnesylation of Ras."],
        [2021, "For decades two chemotherapeutic agents, cytarabine and daunorubicin, remained the backbone of AML therapy protocols."],
        [2009, "Allo-SCT conditioning for myelodysplastic syndrome and AML with clofarabine, cytarabine and ATG."],
        [2001, "To determine the safety and efficacy of arsenictrioxide (arsenictrioxide) in patients with relapsed AML (APL)."],
        [2017, "Midostaurin for the treatment of adult patients with newly diagnosed AML that is FLT3 mutation-positive."],
        [2018, "Inhibition of XPO1 enhances cell death induced by venetoclax in AML via Mcl-1."],
        [2015, "Our results demonstrate that AML cells adhered to stroma exhibited significantly reduced sensitivity to arsenictrioxide."],
        [2016, "Clofarabine Plus Low-Dose Cytarabine Is as Effective as and Less Toxic Than Intensive Chemotherapy in Elderly AML Patients."],
        [2015, "Inhibition of ERK5 enhances cytarabine-induced apoptosis in AML cells."],
        [2015, "cytarabine and anti-CD47 antibody combination therapy eliminates AML THP-1 cells in vivo and in vitro."],
        [2016, "Inhibition of CHK1 enhances cell death induced by the Bcl-2-selective inhibitor venetoclax in AML cells."],
        [1990, "Cytotoxicity and DNA damage caused by idarubicin and its metabolite 4-demethoxy-13-hydroxydaunorubicin in human AML cells."],
        [1995, "Successful treatment of retinoic acid syndrome with high-dose dexamethasone pulse therapy in a child with AML treated with ATRA."],
        [2018, "Bone marrow and/or blood samples from 90 AML patients treated with cytarabine and daunorubicin were included."],
        [2016, "These results highly suggest that the pharmacogenetic analyses of cytarabine influx may be decisive in AML patients."],
        [1997, "Molecular remission in PML/RAR alpha-positive AML by combined all-trans retinoic acid and idarubicin (AIDA) therapy."],
        [2021, "All-trans retinoic acid (ATRA) and pre-upfront arsenictrioxide (arsenictrioxide) have revolutionized the therapy of AML (APL)."],
        [2020, "Treatment with SINE compounds and venetoclax combined led to a reduction in tumor growth in both AML and DLBCL xenografts."],
        [2012, "arsenictrioxide, believed to be a carcinogen and a teratogen, has found its niche in the treatment of AML (APL)."],
        [2006, "Clinical resistance to the kinase inhibitor midostaurin in AML by mutation of Asn-676 in the FLT3 dl-tyrosine kinase domain."],
        [2004, "cytarabine also induced CD80 or CD86 expression in 14 of 21 primary cultured human AML samples."],
        [1999, "Anthracyclines such as daunorubicin (daunorubicin) are typically used to treat AML and can induce drug resistance."],
        [1997, "The inclusion of HD 6MP and ID cytarabine in the treatment of AML in first remission appears to be feasible."],
        [2013, "Idarubicin is superior to daunorubicin in remission induction of de novo AML patients with high MDR1 expression."],
        [2022, "Azacitidine-Induced Pneumonitis in a Patient With AML and Hyperleukocytosis."],
        [2017, "These cells were compared with 66 ex vivo chemorefractory samples from cytarabine-treated AML patients."],
        [1981, "Three patients with AML received high doses of daunorubicin, first in the free form and later as complex with DNA."],
        [2020, "Cost-effectiveness of midostaurin in the treatment of newly diagnosed FLT3-mutated AML in France."],
        [2021, "Subsequently, azacitidine was administered subcutaneously for the AML treatment."],
        [2010, "arsenictrioxide (arsenictrioxide) has shown great promise in the treatment of patients with relapsed or refractory AML (APL)."],
        [2018, "In summary, vyxeos offers an exciting new change to the landscape of AML therapy."],
        [2006, "Role of GSTP1-1 in mediating the effect of arsenictrioxide in the AML cell line NB4."],
        [2014, "Smac mimetic primes apoptosis-resistant AML cells for cytarabine-induced cell death by triggering necroptosis."],
        [2008, "arsenictrioxide (arsenictrioxide) has been recommended for the treatment of refractory cases of AML (APL)."],
        [1994, "A patient is described with undifferentiated AML refractory to two courses of daunorubicin and cytarabine."],
        [2009, "The clinical outcome of FLAG chemotherapy without idarubicin in patients with relapsed or refractory AML."],
        [2008, "Determinants of cerebrospinal fluid arsenic concentration in patients with AML on oral arsenictrioxide therapy."],
        [2021, "Management of AML with venetoclax-based combinations is expected to evolve over the next few years."],
        [2006, "arsenictrioxide (arsenictrioxide, ATO) is a recently developed drug for the effective treatment of AML (APL)."],
        [2012, "arsenictrioxide (As(2)O(3)) is an effective therapeutic against AML and certain solid tumors."],
        [1996, "cytarabine has been shown to induce apoptosis of human AML HL-60 cells."],
        [2017, "Cytotoxic T lymphocytes promote cytarabine-induced AML cell apoptosis via inhibiting Bcl-2 expression."],
        [2021, "Thus, further validating venetoclax as an attractive therapeutic option in the AML treatment landscape."],
        [2002, "Recent studies have shown that arsenictrioxide (As(2)O(3)) can induce complete remission in patients with AML (APL)."],
        [1983, "dexamethasone, fluorouracil or methotrexate on human AML cell line KG-1."],
        [2008, "Previously only acute forms of leukemia particularly AML (APL) have been associated with mitoxantrone treatment in MS."],
        [2020, "azacitidinecitidine Induces NOXA to Prime AML Cells for Venetoclax-Mediated Apoptosis."],
        [2022, "Additionally, arsenictrioxide provoked specific cytoprotective effects in the AML cell lines HL-60 and U937."],
        [2017, "Cytarabine activity in AML blasts can be augmented by degrading the expression of a critical hydrolase."],
        [2001, "A novel differentiation-inducing therapy for AML with a combination of arsenictrioxide and GM-CSF."],
        [2019, "Furthermore, a potentiating effect of HHT on arsenictrioxide was also observed in primary AML cells and AML xenografted tumors."],
        [2004, "gemtuzumab-ozogamicin for relapsed and refractory AML and myeloid sarcomas."],
        [1992, "Bone marrow transplantation versus high-dose cytarabine-based consolidation chemotherapy for AML in first remission."],
        [2011, "In AML patients, we detected increased expression of PRAME and induction of SSX-2 after demethylating therapy with azacitidine."],
        [1996, "Following exposure of the AML patients' blast cells to the anthracyclines, cytarabine."],
        [2009, "Topoisomerase IIalpha expression in AML cells that survive after exposure to daunorubicin or cytarabine."],
        [1996, "etoposide and cytarabine were omitted in the face of AML (AML)."],
        [2021, "Evaluation of arsenic species in leukocytes and granulocytes of AML patients treated with arsenictrioxide."],
        [2021, "azacitidine is the standard of care for myelodysplastic syndromes/low-blast AML (AML) across Western and East Asian patients."],
        [2021, "Outcomes of relapsed or refractory AML patients failing venetoclax-based salvage therapies."],
        [2001, "arsenictrioxide (arsenictrioxide) induces remission in a high proportion of patients with AML (APL) via induction of apoptosis."],
        [2016, "Enhancement of arabinocytosine (cytarabine) toxicity to AML cells by a differentiation agent combination."],
        [1991, "We report a patient with AML who had typical AE due to cytarabine with histopathologic ESS."],
        [1999, "arsenictrioxide has recently been introduced as a promising new agent to treat refractory AML (APL)."],
        [2021, "Our findings suggest that targeting LSCs could control the AML relapse by using IONPs plus cytarabine."],
        [2021, "Outcomes in patients with newly diagnosed TP53-mutated AML with or without venetoclax-based therapy."],
        [2016, "Thus NVP-AUY922 and cytarabine combination therapy might be a prospective strategy for AML treatment."],
        [2015, "Direct binding of arsenictrioxide to AMPK and generation of inhibitory effects on AML precursors."],
        [2016, "Our findings provide new insights into the role of arsenictrioxide and EZH2 in regulating AML progression."],
        [1998, "arsenictrioxide as an inducer of apoptosis and loss of PML/RAR alpha protein in AML cells."],
        [2012, "We conclude that high BMI should not be a barrier to administer high-dose cytarabine-containing regimens for AML induction."],
        [2015, "Lack of objective response of myelodysplastic syndromes and AML to decitabine after failure of azacitidine."],
        [2019, "Cytarabine remains the backbone of therapy in AML (AML)."],
        [2005, "arsenictrioxide (arsenictrioxide) is an effective drug for treatment of AML (APL) and malignant tumors."],
        [2012, "With the introduction of all-trans retinoic acid and arsenictrioxide, the management of AML (APL) has changed dramatically."],
        [2013, "azacitidine is widely used for the treatment of myelodysplastic syndromes (MDS) and AML (AML)."],
        [2020, "DNA has been the presumptive target of the front-line prodrug for AML (AML), cytarabine (cytarabine), since the 1980s."],
        [2017, "arsenictrioxide (arsenictrioxide) has been successfully used in the treatment of AML (APL)."],
        [1998, "arsenictrioxide (arsenictrioxide) has recently been shown to induce complete remission in AML (APL)."],
        [2021, "Inhibition of Nrf2-mediated d-glucose metabolism by brusatol synergistically sensitizes AML to cytarabine."],
        [2008, "All AML patients and 16 MS patients received cytarabine plus idarubicin or fludarabine as induction remission therapy."],
        [2017, "Recently, a single dose of arsenictrioxide (arsenictrioxide) has been found especially effective in treating AML (APL)."],
        [2016, "In contrast, DAC/cytarabine combinations are antagonistic in other Ara-C-sensitive AML cells."],
        [1986, "A patient with myelofibrosis transforming into AML (ANLL) was treated with low doses of cytarabine (cytarabine)."],
        [2001, "These results suggest that dose intensification of cytarabine benefits children with AML and inv(16), as is the case in adults."],
        [2015, "The OPN gene polymorphism confers the susceptibility and response to cytarabine based chemotherapy in Chinese AML patients."],
        [2020, "arsenictrioxide is a drug used for the treatment of AML (APL)."],
        [2006, "We searched for mechanisms of resistance in 6 patients with AML who had relapses upon midostaurin treatment."],
        [2006, "arsenictrioxide, as a single agent, has proven efficacy in inducing molecular remission in patients with AML (APL)."],
        [2016, "SIRT2 might regulate DNR/cytarabine sensitivity in AML cells at least partially through the ERK1/2 pathway."],
        [2002, "Trials with gemtuzumab-ozogamicin (gemtuzumab-ozogamicin) combined with chemotherapy regimens in AML."],
        [2018, "arsenictrioxide (arsenictrioxide) exhibits substantial clinical efficacy in the treatment of AML (APL)."],
        [2008, "arsenictrioxide has remarkable efficacy in AML and is approved by the US Food and Drug Administration for this indication."],
        [2015, "Additional evaluation of arsenictrioxide combined with ACM as a potential therapeutic benefit for AML seems warranted."],
        [2020, "Aprepitant Sensitizes AML Cells to the Cytotoxic Effects of cytarabine in vitro and in vivo."],
        [2014, "Patterns of infection in patients with myelodysplastic syndromes and AML receiving azacitidine as salvage therapy."],
        [2021, "The Combination of Gefitinib With ATRA and arsenictrioxide Induces Myeloid Differentiation in AML Resistant Cells."],
        [2003, "More comprehensive studies are needed to evaluate the apoptotic effect of dexamethasone on AML cells."],
        [2012, "Speciation of arsenictrioxide metabolites in peripheral blood and bone marrow from an AML patient."],
        [1992, "and daunorubicin-mediated cytotoxicity of AML cells and normal myeloid progenitors."],
        [2016, "We retrospectively analyzed 80 subjects diagnosed with AML (AML) who underwent chemotherapy with bolus high-dose mitoxantrone."],
        [2016, "Venetoclax demonstrated activity and acceptable tolerability in patients with AML and adverse features."],
        [2019, "Low-Dose azacitidine with DNMT1 Level Monitoring to Treat Post-Transplantation AML or Myelodysplastic Syndrome Relapse."],
        [2003, "arsenictrioxide in comparison with chemotherapy and bone marrow transplantation for the treatment of relapsed AML."],
        [2004, "FAK+ AML cells displayed significantly higher migration capacities and resistance to daunorubicin, compared with FAK- cells."],
        [2010, "Nausea and vomiting in patients with AML (AML) can be from various causes, including the use of high-dose cytarabine."],
        [2004, "First experience with gemtuzumab-ozogamicin plus cytarabine as continuous infusion for elderly AML patients."],
        [2015, "Evaluating frequency of PML-RARA mutations and conferring resistance to arsenictrioxide-based therapy in relapsed AML patients."],
        [2021, "Long-term quality of life of patients with AML treated with arsenictrioxide vs chemotherapy."],
        [2018, "Cytogenetics and gene mutations influence survival in older patients with AML treated with azacitidine or conventional care."],
        [2020, "Clonal selection in therapy-related myelodysplastic syndromes and AML under azacitidine treatment."],
        [2000, "arsenictrioxide(arsenictrioxide) has proved highly effective in treating both refractory or primary cases of AML (APL)."],
        [2019, "Multiomics of azacitidine-treated AML cells reveals variable and convergent targets that remodel the cell-surface proteome."],
        [2020, "Healthcare utilization in patients with higher-risk MDS/low-blast count AML treated with azacitidine in the 'real-world'."],
        [2018, "Cytarabine is a conventionally used chemotherapeutic agent for treating AML (AML)."],
        [2015, "Cytarabine is the primary chemotherapeutic agent used for treatment of AML (AML)."],
        [1989, "High-dose cytarabine (HDARA-C) is an effective but toxic treatment for AML (AML)."],
        [1996, "The clinical development of cytarabine for the treatment of AML (AML) provides a useful paradigm for the study of this process."],
        [2020, "Cytarabine is an effective treatment for AML with associated toxicities including treatment related mortality (TRM)."],
        [2003, "arsenictrioxide (As(2)O(3)) has been found to be remarkably effective in the treatment of patients with AML (APL)."],
        [1993, "A cell culture model for the treatment of AML with fludarabine and cytarabine."],
        [2003, "Intestinal toxicity during induction chemotherapy with cytarabine-based regimens in adult AML."],
        [2021, "Furthermore, venetoclax (a BCL2 inhibitor) synergistically enhanced the cytotoxicity of DNR in AML cell lines."],
        [2022, "Gilteritinib clinical activity in relapsed/refractory FLT3 mutated AML previously treated with FLT3 inhibitors."],
        [2021, "Thrombocytosis in a patient with AML during treatment with all-trans retinoic acid and arsenictrioxide."],
        [2010, "The purpose of the present study is to evaluate the effects of arsenictrioxide (arsenictrioxide) on human AML NB-4 cells."],
        [2021, "Synergistic effect of chidamide and venetoclax on apoptosis in AML cells and its mechanism."],
        [2013, "Idarubicin is associated with better remission induction of de novo AML patients with high MDR1 expression."],
        [1993, "cytarabine (cytarabine) and etoposide are often used in combination in the treatment of AML (AML)."],
        [2006, "Cytotoxic activity of gemtuzumab-ozogamicin (gemtuzumab-ozogamicin) in AML correlates with the expression of protein kinase Syk."],
        [2020, "Resource utilization and cost effectiveness of treating AML using generic arsenictrioxide."],
        [2018, "All-trans retinoic acid (ATRA) and arsenictrioxide (arsenictrioxide) are essential for AML (APL) treatment."],
        [2007, "Combination of all-trans-retinoic acid and gemtuzumab-ozogamicin in an elderly patient with AML and severe cardiac failure."],
        [2014, "Successful repeated treatment of AML in early relapse with gemtuzumab-ozogamicin alone."],
        [2013, "TGF-β-Neutralizing Antibody 1D11 Enhances Cytarabine-Induced Apoptosis in AML Cells in the Bone Marrow Microenvironment."],
        [2020, "The FDA has approved arsenictrioxide (arsenictrioxide) for AML (APL) treatment."],
        [2015, "As a function of dose, Aa and Ap protected or sensitized AML cells against daunorubicin."],
        [2005, "Two patients with all-trans retinoic acid-resistant AML treated successfully with gemtuzumab-ozogamicin as a single agent."],
        [2016, "Synergisitic and Antagonistic AML Cell Type-specific Responses to azacitidine-2-deoxycitidine and 1-h-D-Arabinofuranoside."],
        [2022, "Long-term follow-up results of cytarabine-containing chemotherapy for AML."],
        [2001, "Efficacy and safety of gemtuzumab-ozogamicin in patients with CD33-positive AML in first relapse."],
        [2017, "Tunneling nanotube (TNT) formation is downregulated by cytarabine and NF-κB inhibition in AML (AML)."],
        [2016, "arsenictrioxide and Tretinoin (AsO/ATRA) for AML (APL)."],
        [2019, "omacetaxinemepesuccinate potentiates the antileukemic activity of arsenictrioxide against AML cells."],
        [2013, "Downregulation of Mcl-1 through GSK-3β activation contributes to arsenictrioxide-induced apoptosis in AML cells."],
        [2018, "Moreover, we show that N6L sensitizes AML cells to doxorubicin and cytarabine treatment."],
        [1993, "Effects of mast cell growth factor on cytarabine mediated AML cell killing."],
        [2016, "arsenictrioxide has achieved great clinical success in the treatment of AML (APL)."],
        [2014, "arsenictrioxide (arsenictrioxide) induces clinical remission in AML and growth inhibition in various cancer cell lines in vitro."],
        [2004, "5'-(3')-nucleotidase mRNA levels in blast cells are a prognostic factor in AML patients treated with cytarabine."],
        [2017, "In addition, cytarabine-induced AML cell apoptosis was enhanced by CTL treatment."],
        [2006, "We describe 2 patients with AML (APL) in whom torsade de pointes (TdP) developed during treatment with arsenictrioxide."],
        [2019, "Synergistic killing effects of omacetaxinemepesuccinate and arsenictrioxide on AML stem cells and the underlying mechanisms."],
        [2013, "arsenictrioxide (arsenictrioxide) is a highly effective agent for treatment of AML (APL)."],
        [2011, "The addition of arsenictrioxide to low-dose cytarabine in older patients with AML does not improve outcome."],
        [1999, "The phosphoinositide 3-kinase/Akt pathway is activated by daunorubicin in human AML cell lines."],
        [2011, "gemtuzumab-ozogamicin combined with chemotherapy is a feasible treatment regimen in AML patients."],
        [1998, "Complete remission after treatment of AML with arsenictrioxide."],
        [2001, "We report a patient with AML (APL) who received two doses of gemtuzumab-ozogamicin for advanced disease."],
        [2006, "arsenictrioxide (arsenictrioxide) induces remission in patients with AML (APL)."],
        [2016, "The role of VDR and BIM in potentiation of cytarabine-induced cell death in human AML blasts."],
        [2020, "Cytarabine is a pyrimidine analogue that is used for the treatment of AML at different doses."],
        [2020, "Gilteritinib in the treatment of relapsed and refractory AML with a FLT3 mutation."],
        [1999, "AV block after arsenictrioxide (arsenictrioxide) treatment for refractory AML is very rare."],
        [2014, "Outcomes of patients with AML (AML) who are refractory to high-dose Cytarabine (HiDAC)-based induction are dismal."],
        [2008, "The triptolide/cytarabine association was also investigated in vitro on primary blast cells from 25 AML patients."],
        [2022, "Epigenetic therapy with chidamide alone or combined with 5-azacitidine exerts antitumour effects on AML cells in vitro."],
        [2020, "arsenictrioxide (arsenictrioxide) is one of the most effective drugs for treatment of AML (APL)."],
        [2005, "Here, azacitidine-CdR induced apoptosis in AML cells (both p53 mutant and wild-type) but not in epithelial or normal PBMCs."],
        [2019, "arsenictrioxide (arsenictrioxide)-containing therapeutic strategies are widely used in the treatment of AML (APL)."],
        [2019, "In the present study, we showed that miR-204 was significantly increased in AML cells after arsenictrioxide treatment."],
        [2017, "enasidenib, a First-in-Class Therapy Targeting AML Harboring Oncogenic IDH2 Mutations."],
        [2019, "A precision medicine test predicts clinical response after idarubicin and cytarabine induction therapy in AML patients."],
        [2011, "Pediatric AML (AML) remains a challenging disease to treat even with intensified cytarabine-based chemotherapy."],
        [2006, "Real-time PCR analysis of PML-RAR alpha in newly diagnosed AML patients treated with arsenictrioxide as a front-line therapy."],
        [2017, "Induction therapy for AML has not changed much since 1973, when the 7+3 regimen of cytarabine and daunorubicin was born."],
        [2014, "Thioredoxin-1 inhibitor PX-12 induces human AML cell apoptosis and enhances the sensitivity of cells to arsenictrioxide."],
        [2002, "CMV infection occurred rarely during cytarabine and anthracyclin based induction therapy for AML or RAEB."],
        [2017, "arsenictrioxide (arsenictrioxide) is highly effective in the treatment of patients with AML (APL)."],
        [2019, "MicroRNA-204 Potentiates the Sensitivity of AML Cells to arsenictrioxide."],
        [2010, "Auricular oedema and dyshidrotic eczema in a patient with AML treated with cytarabine."],
        [2019, "Furthermore, SIRT3 enhanced oxidative phosphorylation (OxPhos) in AML cells under both basic and cytarabine-treated conditions."],
        [2019, "Overexpression of miR-204 potentiated arsenictrioxide-induced AML cell growth inhibition and apoptosis."],
        [2019, "cytarabine is the clinically most relevant cytotoxic agent for AML treatment."],
        [2009, "The patient was diagnosed with AML (APL) and was treated with all-trans retinoic acid (ATRA) and idarubicin."],
        [2012, "Addition of gemtuzumab-ozogamicin to induction chemotherapy improves survival in older patients with AML."],
        [2003, "arsenictrioxide (arsenictrioxide) therapy for AML in the setting of hematopoietic stem cell transplantation."],
        [2012, "Upfront maintenance therapy with arsenictrioxide in AML provides no benefit for non-t(15;17) subtype."],
        [2000, "Leukocytosis and the retinoic acid syndrome in patients with AML treated with arsenictrioxide."],
        [1991, "Treatment with HGFs resulted in [3H] cytarabine DNA incorporation that was significantly higher in AML blasts versus NBMMC."],
        [2019, "arsenictrioxide (arsenictrioxide) is a drug commonly used for the treatment of AML (APL)."],
        [2019, "Maintenance therapy such as azacitidine after allo-HSCT for AML with FUS-ERG may be clinically meaningful."],
        [2014, "Health economic impact of high-dose versus standard-dose cytarabine induction chemotherapy for AML."],
        [2015, "Cytarabine is used in the treatment of AML (AML)."],
        [2007, "Results of compassionate therapy with intrathecal depot liposomalcytarabine in AML meningeosis."],
        [1999, "Leukemic cells from ten patients with AML (AML) were sorted on the basis of in vitro daunorubicin (daunorubicin) uptake."],
        [2017, "Influence of cytarabine metabolic pathway polymorphisms in AML induction treatment."],
        [2016, "arsenictrioxide (AsO3) is used for the treatment of AML in combination with retinoids."],
        [2021, "Effects of co-administration of arsenictrioxide and Schiff base oxovanadium complex on the induction of apoptosis in AML cells."],
        [2016, "Cytosine arabinoside and daunorubicin induction therapy in a patient with AML on chronic hemodialysis."],
        [2007, "midostaurin has proven activity in the treatment of AML (AML)."],
        [2013, "We identified 97 patients with AML diagnosed after the age of 60 and treated with cytarabine-based induction chemotherapy."],
        [1994, "Long-term results following treatment of newly-diagnosed AML with continuous-infusion high-dose cytarabine."],
        [2000, "arsenictrioxide has been shown to be effective in leukemia, and AML in particular, both in vitro and in vivo."],
        [2011, "Inhibition of histone deacetylases 1 and 6 enhances cytarabine-induced apoptosis in pediatric AML cells."],
        [2014, "RUNXOR was upregulated in AML samples and in response to cytarabine treatment in vitro."],
        [2022, "Quantification of Venetoclax for Therapeutic Drug Monitoring in Chinese AML Patients by a Validated UPLC-MS/MS Method."],
        [2007, "Sixty patients with high-risk MDS or AML following MDS were treated with standard doses of daunorubicin and cytarabine."],
        [1989, "Low-dose cytarabine therapy for AML in elderly patients."],
        [2015, "Consolidation therapy of arsenictrioxide alternated with chemotherapy achieves remarkable efficacy in newly diagnosed AML."],
        [2019, "Using a genome-wide CRISPR/Cas9 screen in human AML, we identified genes whose inactivation sensitizes AML blasts to venetoclax."],
        [2006, "We have previously established the activity of clofarabine plus cytarabine in AML relapse."],
        [2001, "Effect of all-trans retinoic acid and arsenictrioxide on tissue factor expression in AML cells."],
        [2006, "Use of all-trans retinoic acid plus arsenictrioxide as an alternative to chemotherapy in untreated AML."],
        [2010, "arsenictrioxide in the treatment of AML is relatively safe with minimal side effects."],
        [2014, "The experience with gemtuzumab-ozogamicin has highlighted both the potential value and limitations of antibodies in AML (AML)."],
        [2010, "arsenictrioxide cures AML (APL) by initiating PML/RARA oncoprotein degradation, through sumoylation of its PML moiety."],
        [2015, "Anti-leukemic effect of sodium metaarsenite (KML001) in AML with breaking-down the resistance of cytarabine."],
        [2016, "The combination of daunorubicin and cytarabine is the cornerstone of induction therapy for AML (AML)."],
        [2018, "arsenictrioxide (TX) has been used successfully for the treatment of AML (APL) patients."],
        [2000, "gemtuzumab-ozogamicin is a promising agent in the treatment of patients with AML that expresses CD33."],
        [2010, "Characteristics and outcome of patients with AML refractory to 1 cycle of high-dose cytarabine-based induction chemotherapy."],
        [2019, "Cryopreserved BMMC samples from 49 AML patients were characterized for ex vivo growth and sensitivity to cytarabine."],
        [2005, "GM-CSF and low-dose cytarabine in high-risk, elderly patients with AML or MDS."],
        [2004, "arsenictrioxide (arsenictrioxide) is approved for the treatment of AML and is under investigation for other malignancies."],
        [1984, "The use of intermediate dose cytarabine (ID cytarabine) in the treatment of AML in relapse."],
        [2006, "Leukocytosis and retinoic acid syndrome in patients with AML treated with arsenictrioxide."],
        [2022, "Venetoclax plus cytarabine therapy is approved for elderly AML (AML) patients and needs further improvement."],
        [1980, "Cyclophosphamide, cytarabine and methotrexate versus cytarabine and thioguanine for AML in adults."],
        [2002, "Resistance to cytarabine (cytarabine) is a major problem in treatment of patients with AML (AML)."],
        [1983, "The effects of dexamethasone and tetradecanoyl phorbol acetate on plasminogen activator release by human AML cells."],
        [2001, "Combined effect of all-trans retinoic acid and arsenictrioxide in AML cells in vitro and in vivo."],
        [2005, "We therefore conclude that p73 is a relevant target for methylation-dependent efficacy of azacitidine-CdR in AML cells."],
        [2012, "All-trans-retinoic acid, idarubicin, and IV arsenictrioxide as initial therapy in AML (APML4)."],
        [2017, "We report two cases of fetal myelosuppression following high-dose cytarabine administration for AML (AML)."],
        [1993, "The regimen containing BHAC (or cytarabine), DNR, and 6-MP may be useful as induction chemotherapy for AML-M0."],
        [2017, "Cytarabine (cytarabine) and Daunorubicin (Dnr) forms the backbone of AML (AML) therapy."],
        [1996, "Peripheral leukaemic cells from 10 patients with AML were incubated with daunorubicin (daunorubicin)."],
        [2019, "In vitro stability of arsenictrioxide-liposome encapsulates for AML treatment."],
        [2003, "Daunorubicin (daunorubicin) is one of the most important cytotoxic agents in the treatment of AML (AML)."],
        [2019, "Time course of arsenic species in red blood cells of AML (APL) patients treated with single agent arsenictrioxide."],
        [2012, "arsenictrioxide (arsenictrioxide) is presently the most active single agent in the treatment of AML (APL)."],
        [1992, "Treatment of AML in the elderly with low-dose cytarabine, hydroxyurea, and calcitriol."],
        [2009, "arsenictrioxide, As(2)O(3), has successfully been used to treat AML (APL)."],
        [2015, "azacitidine has been investigated in older AML patients."],
        [2020, "Adult patients with r/r AML were treated with chidamide, decitabine, cytarabine, aclarubicin, and G-CSF (CDCAG)."],
        [2022, "Venetoclax has transformed the therapeutic landscape of AML (AML)."],
        [2020, "All-trans retinoic acid (ATRA) and arsenictrioxide (arsenictrioxide) are effective induction therapy for AML (APL)."],
        [2005, "Paricalcitol, when combined with arsenictrioxide, showed a markedly enhanced antiproliferative effect against AML (AML) cells."],
        [2000, "Heterogeneity of isolated mononuclear cells from patients with AML affects cellular accumulation and efflux of daunorubicin."],
        [2018, "arsenictrioxide (arsenictrioxide) is used as a therapeutic agent in the treatment of AML (APL)."],
        [2018, "The AML (APL) drug arsenictrioxide (arsenictrioxide), causes hepatotoxicity."],
        [2020, "In summary, vyxeos offers finally something new in the landscape of AML therapy."],
        [1993, "One of the differences between AML (AML) and acute lymphoblastic leukemia (ALL) is their sensitivity to vincristine."],
        [2008, "Idarubicin is another active AML drug, which has not yet been tested with clofarabine."],
        [2020, "The treatment of high-risk AML (APL) remains an area of contention as arsenictrioxide is not approved for this indication."],
        [2016, "Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups."],
        [2014, "gemtuzumab-ozogamicin was the first example of antibody-directed chemotherapy in cancer, and was developed for AML."],
        [2014, "We present the first Jehovah's Witness patient with AML (AML) treated successfully with azacitidine."],
        [2020, "Abivertinib synergistically strengthens the anti-leukemia activity of venetoclax in AML in a BTK-dependent manner."],
        [2020, "Our findings support further investigation of midostaurin as a chemosensitizing agent in AML patients without FLT3 mutations."],
        [2022, "In the United States, oral azacitidine is unlikely to be cost-effective for AML patients at current prices."],
        [2020, "The distal muscular atrophy is one of side effects of arsenictrioxide (arsenictrioxide) for AML therapy."],
        [2017, "DNA-PK inhibition alleviated mitoxantrone resistance for AML cells on and off stromal cells."],
        [2019, "This gene signature was enriched in cytarabine-resistant AML cells in a patient-derived xenograft model."],
        [2008, "gemtuzumab-ozogamicin (gemtuzumab-ozogamicin) monotherapy is reported to yield a 20-30% response rate in advanced AML (AML)."],
        [2020, "The approved FLT3 dl-tyrosine kinase inhibitors (TKIs) midostaurin and gilteritinib improve survival in AML with FLT3 mutations."],
        [2017, "Cytarabine is considered the most effective chemotherapeutic option in AML (AML)."],
        [2010, "The expression of p38, ERK1 and Bax proteins has increased during the treatment of newly diagnosed AML with arsenictrioxide."],
        [2020, "Resistance to the chemotherapeutic drug azacitidine (5'-AZA) is a major obstacle in the treatment of patients with AML (AML)."],
        [2000, "arsenictrioxide, like all-trans-retinoic acid (RA), induces differentiation of AML (APL) cells in vivo."],
        [2009, "Prospective minimal residual disease monitoring to predict relapse of AML and to direct pre-emptive arsenictrioxide therapy."],
        [2011, "arsenictrioxide (arsenictrioxide) has been proven to be highly effective in adults with newly diagnosed or relapsed AML (APL)."],
        [2014, "In addition to treating AML (APL), arsenictrioxide (arsenictrioxide) also suppresses other solid tumors, such as HCC."],
        [2008, "In the last decade, arsenictrioxide (arsenictrioxide) has been used very successfully to treat AML (APL)."],
        [2020, "Effects of the multi-kinase inhibitor midostaurin in combination with chemotherapy in models of AML."],
        [2019, "Invasive fungal infections in AML treated with venetoclax and hypomethylating agents."],
        [2018, "dexamethasone may improve the outcome of AML patients receiving intensive chemotherapy."],
        [2010, "Voreloxin is in clinical studies, as a single agent and in combination with cytarabine, for the treatment of AML (AML)."],
        [2010, "arsenictrioxide (As(2)O(3)), a Food and Drug Administration (FDA) approved drug is successfully being used to treat AML (APL)."],
        [2015, "Tamibarotene in patients with AML relapsing after treatment with all-trans retinoic acid and arsenictrioxide."],
        [1996, "It has been shown recently in China that arsenictrioxide (arsenictrioxide) is a very effective treatment for AML (APL)."],
        [2019, "Melatonin enhances arsenictrioxide-induced cytotoxicity by modulating autophagy in an AML cell line."],
        [2018, "Additionally, the effect of blocking CXCR4 and TGF-β1 on AML cells was tested with and without the addition of cytarabine."],
        [1979, "Enhanced cytarabine accumulation after administration of MTX was also observed in human AML cells."],
        [2020, "UGT1A1 genotype influences clinical outcome in patients with intermediate-risk AML treated with cytarabine-based chemotherapy."],
        [2001, "Idarubicin, cytarabine, and topotecan in patients with refractory or relapsed AML and high-risk myelodysplastic syndrome."],
        [2015, "Differentiation syndrome in AML after treatment with azacitidine."],
        [2006, "Recently, patients with AML (APL) have experienced significant clinical gains after treatment with arsenictrioxide."],
        [2014, "arsenictrioxide (arsenictrioxide) is a novel form of therapy that has been found to aid AML (APL) patients."],
        [2010, "Mechanisms of resistance against midostaurin in resistant FLT3-ITD positive human AML cells."],
        [2017, "arsenictrioxide (arsenictrioxide) is an old drug that has recently been reintroduced as a therapeutic agent for AML (APL)."],
        [2017, "Characteristics and outcome of patients with therapy-related AML front-line treated with or without arsenictrioxide."],
        [2019, "This study aimed to examine the effects of arsenictrioxide (arsenictrioxide) on EVI-1 in AML (AML)."],
        [2020, "The standard first-line treatment for AML (AML) is a combination of cytarabine and anthracyclines."],
        [2001, "Cytosine arabinoside, idarubicin and divided dose etoposide for the treatment of AML in elderly patients."],
        [2015, "Knockdown of homeobox A5 by small hairpin RNA inhibits proliferation and enhances cytarabine chemosensitivity of AML cells."],
        [2003, "Multidrug resistance protein attenuates gemtuzumab-ozogamicin-induced cytotoxicity in AML cells."],
        [2010, "arsenictrioxide (As(2)O(3), ATO) has been successfully applied to treat AML (APL)."],
        [2005, "Combined treatment of AML cells by cytarabine or IDA with anti-CD33 mAb resulted in higher levels of SHP-1 phosphorylation."],
        [2019, "arsenictrioxide (arsenictrioxide) is widely applied to treat AML (APL)."],
        [2004, "This study has been carried out in our clinic in order to evaluate the efficiency of the AML protocol which includes idarubicin."],
        [2015, "Ex vivo cytarabine sensitivity was determined in primary AML samples using MTT assay."],
        [2022, "Gilteritinib is approved for relapsed or refractory FLT3 mutated AML as monotherapy based on the ADMIRAL study."],
        [2001, "Combination chemotherapy utilizing continuous infusion of intermediate-dose cytarabine for refractory or recurrent AML."],
        [2004, "arsenictrioxide (As(2)O(3)) treatment induces apoptosis in AML cells through an incompletely understood mechanism."],
        [2001, "Intensive timed sequential remission induction chemotherapy with high-dose cytarabine for childhood AML."],
        [2020, "Megakaryocytic Expansion in Gilteritinib-Treated AML Patients Is Associated With AXL Inhibition."],
        [2008, "Combinations with cytarabine in AML are feasible and effective."],
        [2022, "Twenty-six AML patients who relapsed after allo-HSCT were enrolled and treated with venetoclax plus azacitidine and DLI."],
        [2012, "High Dose cytarabine (HiDAC) is a safe and cost effective consolidation treatment for AML patients in complete remission."],
        [2007, "The role of gemtuzumab-ozogamicin in the treatment of AML patients."],
        [2005, "Efficacy of gemtuzumab-ozogamicin on ATRA- and arsenic-resistant AML (APL) cells."],
        [2015, "azacitidine sensitization to arsenictrioxide treatment was re-capitulated also in primary AML samples."],
        [2020, "Recently, novel drugs like venetoclax plus azacitidine (VA) were reported to have promising efficacy in refractory AML (AML)."],
        [1993, "No difference of intracellular daunorubicin accumulation was observed between CD34+ and CD34- AML cells of 4 P-170- patients."],
        [2010, "Promising reports exist regarding the use of arsenictrioxide (arsenictrioxide) as first-line treatment in AML (APL)."],
        [2022, "Analysis of risk factors for early death in patients with AML treated with arsenictrioxide."],
        [2013, "We explored the differences by scrutinizing a case of gemtuzumab-ozogamicin (gemtuzumab-ozogamicin) in patients with AML (AML)."],
        [2019, "Identification of predictive genetic signatures of Cytarabine responsiveness using a 3D AML model."],
        [2003, "blast cells from 15 children with ALL and 9 with AML were exposed to a range of concentrations of cytarabine +/- aphidicolin."],
        [2020, "One hundred seventy-nine patients with R/R AML received ivosidenib and 214 received enasidenib."],
        [2006, "Resistance to cytarabine (cytarabine) is a major problem in the treatment of patients with AML (AML)."],
        [2013, "Preclinical data indicate that DAC is much more effective against human AML than cytarabine."],
        [2022, "Nrf2 overexpression increases the resistance of AML to cytarabine by inhibiting replication factor C4."],
        [2015, "Effects on primary human AML cell viability and proliferation of low-dose cytarabine (0.01-0.5 μM) were also assessed."],
        [2011, "Use of gemtuzumab-ozogamicin combined with conventional chemotherapy in patients with AML."],
        [2010, "Gefitinib enhances arsenictrioxide (AS2O3)-induced differentiation of AML cell line."],
        [2016, "The clinical use of arsenictrioxide (arsenictrioxide) in the treatment of AML (APL) is limited by its cardiotoxic side effects."],
        [2019, "arsenictrioxide [arsenictrioxide, arsenite (AsIII) in solution] has been applied successfully for the treatment of AML (APL)."],
        [2000, "Pathologic, cytogenetic and molecular assessment of AML patients treated with arsenictrioxide (arsenictrioxide)."],
        [1998, "Two reports from China have suggested that arsenictrioxide can induce complete remissions in patients with AML (APL)."],
        [2022, "To address whether Curcumin has synergistic effect with cytarabine (cytarabine) in treating AML (AML)."],
        [2022, "gemtuzumab-ozogamicin (gemtuzumab-ozogamicin) improves outcomes when added to intensive AML chemotherapy."],
        [2018, "BET Inhibition Suppresses S100A8 and S100A9 Expression in AML Cells and Synergises with Daunorubicin in Causing Cell Death."],
        [2005, "Heat shock protein 90 inhibition sensitizes AML cells to cytarabine."],
        [2005, "Serial studies of methylation of CDKN2B and CDKN2A in relapsed AML treated with arsenictrioxide."],
        [1975, "Thirty-seven adults with AML (AML) were treated with a combination of daunorubicin, cytarabine."],
        [2011, "Cytarabine (cytarabine) is an important drug in the treatment of AML (AML)."],
        [1992, "Long-term outcome of high-dose cytarabine-based consolidation chemotherapy for adults with AML."],
        [2004, "JNK activation is a mediator of arsenictrioxide-induced apoptosis in AML cells."],
        [1991, "Oral idarubicin and low dose cytarabine as the initial treatment of AML in elderly patients."],
        [2012, "arsenictrioxide (arsenictrioxide) is used, in current practice, as an effective chemotherapeutic agent for AML (APL)."],
        [2019, "Herein we aimed at exploring potential pre-clinical treatment strategies to surmount Cytarabine resistance in human AML cells."],
        [2022, "Venetoclax is used for the priority treatment of elderly patients with AML (AML)."],
        [2021, "Pharmacokinetics and pharmacogenetics of liposomalcytarabine in AML patients treated with vyxeos."],
        [2019, "Targeting Mitochondrial Structure Sensitizes AML to Venetoclax Treatment."],
        [1993, "The optimal dose and schedule of cytarabine in induction chemotherapy of newly diagnosed AML is not established."],
        [1990, "The original LBN AML is sensitive to the chemotherapeutic agent cyclophosphamide (CY)."],
        [2017, "In vitro, exogenous IL-6 reduced mitoxantrone-induced apoptosis in cell lines and primary pediatric AML samples."],
        [1991, "Low dose cytarabine (LDARAC) has been commonly used in the treatment of AML (AML) in elderly patients."],
        [2022, "Venetoclax enhances NK cell killing sensitivity of AML cells through the NKG2D/NKG2DL activation pathway."],
        [2018, "arsenictrioxide (arsenictrioxide) is a promising new regimen for the treatment of AML (APL)."],
        [2022, "Practical tips for managing FLT3 mutated AML with midostaurin."],
        [2015, "azacitidine sensitizes AML cells to arsenictrioxide by up-regulating the arsenic transporter aquaglyceroporin 9."],
        [1994, "Structural analysis of the deoxycytidine kinase gene in patients with AML and resistance to cytarabine."],
        [1994, "Combined antileukemic activity of pIXY 321 and cytarabine against human AML cells."],
        [1994, "In three AML samples at diagnosis and at their relapse, cytarabine incorporation into the DNA was determined."],
        [2022, "Furthermore, we discovered that inhibiting SPAG1 impacted AML cell susceptibility to venetoclax."],
        [2013, "Azacitidine fails to eradicate leukemic stem/progenitor cell populations in patients with AML and myelodysplasia."],
        [2011, "arsenictrioxide (As(2)O(3)) is an effective treatment for relapsed or refractory AML (APL)."],
        [2015, "The mechanism of synergistic effects of arsenictrioxide and sirolimus in AML cell lines lacking typical t(15;17) translocation."],
        [2017, "All-trans retinoic acid and arsenictrioxide fail to derepress the monocytic differentiation driver Irf8 in AML cells."],
        [1999, "Treatment of poor prognosis AML patients using valspodar (valspodar) plus mitoxantrone, etoposide, and cytarabine (PSC-MEC)."],
        [2002, "Advances in the management of AML and other hematologic malignancies with arsenictrioxide."],
        [2022, "Selective BCL2 inhibitor venetoclax has been approved to treat hematological malignancies including AML (AML)."],
        [2012, "The cytarabine (cytarabine)-based chemotherapy is the major remedial measure for AML (AML)."],
        [1999, "It was recently reported that arsenictrioxide (As(2)O(3)) can induce complete remission in patients with AML (APL)."],
        [2020, "In the clinical setting, chemotherapy including anthracyclines and cytarabine remains a gold standard for AML treatment."],
        [2017, "Furthermore, AZA sensitized AML cells to cytarabine chemotherapy."],
        [1997, "Cytarabine ocfosfate (SPAC) was administered orally to 19 patients with AML (AML) and myelodysplastic syndrome (MDS)."],
        [2013, "In initial ALL, an impact on long-term response was shown in ITRT for 13 drugs, while in initial AML only for cytarabine."],
        [1995, "Idarubicin in combination with cytarabine and etoposide in the treatment of post myelodysplastic syndrome AML (MDS-AML)."],
        [2018, "arsenictrioxide promoting ETosis in AML through mTOR-regulated autophagy."],
        [2022, "Total Marrow and Lymphoid Irradiation with Post-Transplantation Cyclophosphamide for Patients with AML in Remission."],
        [2022, "Curcumin sensitizes response to cytarabine in AML by regulating intestinal microbiota."],
        [2018, "Intravenous arsenictrioxide (arsenictrioxide) has been adopted as the first-line treatment for AML (APL)."],
        [2022, "The BCL2 inhibitor venetoclax has established therapeutic roles in chronic lymphocytic leukemia (CLL) and AML (AML)."],
        [2019, "Purine analogs like cytarabine (cytarabine) are a mainstay for treating AML (AML)."],
        [2012, "Role of minimal residual disease monitoring in AML treated with arsenictrioxide in frontline therapy."],
        [2020, "AZD4320 demonstrates monotherapy activity in patient-derived AML and venetoclax-resistant xenograft models."],
        [2002, "Neutropenic colitis after treatment of AML with idarubicin and cytarabine."],
        [1997, "Long-term outcome of high-dose cytarabine-based consolidation chemotherapy for older patients with AML."],
        [2015, "Hyperoside enhances the suppressive effects of arsenictrioxide on AML cells."],
        [2019, "Clinical and economic analysis of patients with AML by FLT3 status and midostaurin use at a Comprehensive Cancer Center."],
        [2015, "gemtuzumab-ozogamicin in combination with intensive chemotherapy in relapsed or refractory AML."],
        [2020, "Economic Evaluation of azacitidine in Elderly Patients with AML with High Blast Counts."],
        [1988, "cytarabine is the most important drug in the clinical chemotherapy of AML."],
        [2018, "Clonal heterogeneity of AML treated with the IDH2 inhibitor enasidenib."],
        [2004, "Bone marrow necrosis in a patient with AML during re-induction therapy with arsenictrioxide."],
        [2022, "Curcumin treatment sensitized response to cytarabine in MNCs of AML mice, but had no direct effect on AML cell lines."],
        [1987, "Low dose arabinosyl cytosine (cytarabine) is effective for treatment of AML (ANLL)."],
        [2008, "Alleviation of the drug-resistant phenotype in idarubicin and cytarabine double-resistant AML cells by indomethacin."],
        [1992, "Both MAbs reacted positively in 1 patient with AML (ANLL) at diagnosis who achieved remission with teniposide and cytarabine."],
        [1991, "High-dose cytarabine and daunorubicin induction and postremission chemotherapy for the treatment of AML in adults."],
        [2015, "Azacitidine for the treatment of relapsed and refractory AML in older patients."],
        [1989, "Standard induction and low dose cytarabine treatment in patients over 60 with AML or MDS."],
        [2015, "TERT over-expression significantly attenuated azacitidine-mediated DNA damage, telomere dysfunction and apoptosis of AML cells."],
        [1990, "Rapid Remission Induction and Improved Disease Free Survival in AML Using Daunorubicin, cytarabine, and lomustine."],
        [2015, "Cost-Effectiveness Analysis of Treating AML Patients With arsenictrioxide and Retinoic Acid in the United States."],
        [2007, "Therapy-related AML following mitoxantrone therapy in a patient with multiple sclerosis."],
        [2016, "For the treatment of AML (AML), purine analogs, like clofarabine and cytarabine act synergistically."],
        [2015, "Candidate cytarabine metabolizing gene expression in primary AML cells is proposed to account for this variation."],
        [2022, "Venetoclax combination therapy in AML and myelodysplastic syndromes."],
        [2018, "Patients using docetaxel and cyclophosphamide (TC) were not at increased risk for AML or MDS."],
        [1995, "In summary, high-dose cytarabine/DNR consolidation can improve the long-term outcome of a subgroup of de novo AML patients."],
        [2007, "We report the results of compassionate therapy with IT depot liposomalcytarabine in 10 patients with AML with CNS involvement."],
        [2005, "arsenictrioxide has shown great promise in the treatment of patients with relapsed or refractory AML (APL)."],
        [2022, "The development of Venetoclax, a potent oral BH3 (BCL-2 homology domain 3) mimetic, has transformed the AML treatment."],
        [2022, "By coculture with cells, this study revealed that the AML cells resisted apoptosis induced by the anticancer drug cytarabine."],
        [2014, "Dual epigenetic targeting with panobinostat and azacitidine in AML and high-risk myelodysplastic syndrome."],
        [2022, "We describe real-world venetoclax + HMA treatment practices and outcomes in patients with ND AML in the US."],
        [2022, "Polygenic cytarabine Response Score Identifies Pediatric Patients With AML in Need of Chemotherapy Augmentation."],
        [2015, "arsenictrioxide (arsenictrioxide), an antitumor agent, is widely used for treating AML (APL), in which it induces apoptosis."],
        [2002, "ALL samples were significantly more sensitive than AML samples to melphalan, doxorubicin and etoposide, but not to cytarabine."],
        [2019, "gemtuzumab-ozogamicin was approved for the treatment of AML by the US Food and Drug Administration in September 2017."],
        [1994, "Benefit of high-dose cytarabine-based consolidation chemotherapy for adults with AML."],
        [2022, "Azacitidine-induced reconstitution of the bone marrow T cell repertoire is associated with superior survival in AML patients."],
        [2016, "CD33 is variably expressed on AML (AML) blasts and is targeted by gemtuzumab-ozogamicin (gemtuzumab-ozogamicin)."],
        [2014, "arsenictrioxide (arsenictrioxide) is a promising antitumor agent used to treat AML (APL) and, recently solid tumor."],
        [1990, "Concordant changes of pyrimidine metabolism in blasts of two cases of AML after repeated treatment with cytarabine in vivo."],
        [1996, "Generation of reactive oxygen intermediates after treatment of blasts of AML with cytarabine."],
        [2015, "Azacitidine improves the T-cell repertoire in patients with myelodysplastic syndromes and AML with multilineage dysplasia."],
        [2018, "In addition, we show that JQ1 synergises with daunorubicin in causing AML cell death."],
        [2013, "High frequency of streptococcal bacteraemia during childhood AML therapy irrespective of dose of cytarabine."],
        [2022, "Evidence that a venetoclax (VEN)-combined regimen is effective in relapsed/refractory AML (R/R AML) is emerging."],
        [2017, "These results support clinical testing of combined venetoclax and alvocidib for the treatment of AML and advanced MDS."],
        [2022, "Lymphocyte Exhaustion in AML Patients and Impacts of HMA/Venetoclax or Intensive Chemotherapy on Their Biology."],
        [2018, "Quantitative assessment of the sensitivity of dormant AML cells to the BAD mimetics venetoclax and ABT-737."],
        [2017, "Primary AML samples with high ex-vivo IC50 to cytarabine, ATO, Dnr had significantly high NRF2 RNA expression."],
        [2017, "The impact of 10 polymorphisms in cytarabine metabolic pathway genes were evaluated in 225 adult de novo AML patients."],
        [2018, "We report an AML (AML) patient who developed massive pericardial effusion after a second cytarabine exposure."],
        [2019, "However, no randomized clinical trials have directly compared GLAS + low-dose cytarabine with other AML treatments."],
        [2020, "Impact of TP53 mutations in AML patients treated with azacitidine."],
        [2002, "arsenictrioxide (arsenictrioxide) can induce clinical remission in patients with AML (APL) through induction of apoptosis."],
        [2013, "Aurora B inhibitor barasertib and cytarabine exert a greater-than-additive cytotoxicity in AML cells."],
        [2014, "In summary, children with DS and AML should be treated with a moderate-intensity cytarabine-based regimen with curative intent."],
        [2020, "Gilteritinib is a FLT3 kinase inhibitor approved for FLT3-mutated AML (AML)."],
        [2022, "Liposome encapsulating cytarabine (CYT) and daunorubicin (daunorubicin) is applied for treating AML (AML) patients."],
        [2005, "Patients with AML and an activating mutation in FLT3 respond to a small-molecule FLT3 dl-tyrosine kinase inhibitor, midostaurin."],
        [2000, "We treated 53 patients with newly diagnosed AML (AML) with high-dose cytarabine-based chemotherapy followed by ATRA."],
        [2022, "arsenictrioxide (arsenictrioxide) is the standard treatment for relapsed AML (APL)."],
        [1981, "vincristine, and 6alpha-methylprednisone (ROAP) to 91 patients with AML who were 50 yr of age or older."],
        [2003, "gemtuzumab-ozogamicin (gemtuzumab-ozogamicin) is a novel immunoconjugate therapy for AML (AML)."],
        [2014, "Cytarabine (cytarabine) is one of the most effective drugs for the treatment of patients diagnosed with AML (AML)."],
        [2017, "High-dose ascorbate and arsenictrioxide selectively kill AML and AML blasts in vitro."],
        [2002, "The antimetabolite thioguanine (6-TG) is utilized in the management of AML (AML)."],
        [1997, "Furthermore, 11 AML and four ALL patients were treated with fractionated daunorubicin at a dose of 50 mg/m2/week."],
        [2022, "arsenictrioxide and Venetoclax Synergize against AML Progenitors by ROS Induction and Inhibition of Nrf2 Activation."],
        [2020, "Enasidenib is an FDA-approved isocitrate dehydrogenase 2 (IDH2) inhibitor, which is used in the treatment of AML (AML)."],
        [2017, "Despite aggressive chemotherapy including mitoxantrone and etoposide, relapse occurs for almost half of children with AML (AML)."],
        [2018, "Anthracyclines in combination with cytarabine have been the standard therapy for AML (AML) for decades with high efficacy."],
        [1991, "hydrocortisonecypionate in culture protects the blast cells in AML from the lethal effects of cytarabine."],
        [2017, "Further study will confirm them as biomarkers for AML patients after cytarabine-based chemotherapy."],
        [1987, "Thirty-eight patients with AML (AML) were treated with mitoxantrone (Mto) combined with cytarabine (cytarabine)."],
        [2013, "Cytarabine (cytarabine) has served as the backbone of AML (AML) treatment for nearly forty years."],
        [2006, "Long-term results of an ultra low-dose cytarabine-based regimen for the treatment of AML in children with Down syndrome."],
        [2005, "Remission induction in a Jehovah's witness patient with AML using gemtuzumab-ozogamicin."],
        [2010, "arsenictrioxide enhances the cytotoxic effect of thalidomide in a KG-1a human AML cell line."],
        [2003, "Aphidicolin significantly increased sensitivity to cytarabine in blast cells from both ALL (p=0.001) and AML (p0.05)."],
        [2020, "The effects of cytarabine combined with ginsenoside compound K synergistically induce DNA damage in AML cells."],
        [2001, "This assay was applied to the analysis of serum from AML patient treated by high doses cytarabine (3 g/m2 body surface)."],
        [2019, "Surmounting Cytarabine-resistance in AML cells and specimens with a synergistic combination of hydroxyurea and zidovudine."],
        [2019, "arsenictrioxide is an approved chemotheraputic agent for the treatment of AML (APL)."],
        [1991, "14 patients with AML (AML) and 7 with myelodysplastic syndrome (MDS) were treated with cytarabine in low dosage."],
        [2012, "AML (AML) is the most common type of adult leukemia for which cytarabine.based chemotherapy is the main treatment."],
        [1986, "A critical appraisal of low-dose cytarabine in patients with AML and myelodysplastic syndromes."],
        [2020, "Venetoclax is a highly selective BCL-2 inhibitor that has been approved by the FDA for treating elderly AML patients."],
        [2020, "Biomarkers of gemtuzumab-ozogamicin Response for AML Treatment."],
        [2009, "The standard therapeutic approaches for AML (AML) continue to be based on anthracyclines and cytarabine."],
        [2006, "Treatment of AML with arsenictrioxide without ATRA and/or chemotherapy."],
        [2016, "arsenictrioxide (arsenictrioxide) has demonstrated clinical efficacy in AML (APL) and in vitro activity in various solid tumors."],
        [2016, "arsenictrioxide-based therapy is suitable for patients with psoriasis-associated AML - A retrospective clinical study."],
        [1992, "Maintenance with low-dose cytarabine for AML in complete remission."],
        [2009, "Low-dose arsenictrioxide can effectively alleviate AML (APL)."],
        [2020, "arsenictrioxide (arsenictrioxide; ATO) has shown to be an effective anti-cancer drug targeting AML (APL)."],
        [2020, "Advances in AML (AML) genomics and targeted therapies include the recently approved BCL2 inhibitor venetoclax."],
        [2017, "Intensive combination chemotherapy including gemtuzumab-ozogamicin emerged as an effective salvage therapy in refractory AML."],
        [2021, "arsenictrioxide synergistically promotes the antileukaemic activity of venetoclax by downregulating Mcl-1 in AML cells."],
        [1992, "A six year old Chinese boy with relapsed AML (APML) failed to respond to reinduction with Daunorubicin and Cytarabine infusion."],
        [2013, "arsenictrioxide has received approval for use in patients with relapsed AML for remission induction."],
        [2012, "High-dose cytarabine induction is well tolerated and active in patients with de novo AML older than 60 years."],
        [1995, "We evaluated the efficacy and toxicity of aclarubicin for AML (ANLL) refractory to daunorubicin in childhood."],
        [2003, "arsenictrioxide (arsenictrioxide) has been used as an effective chemotherapy agent for some human cancer, such as AML."],
        [2015, "Resistance to cytarabine and anthracycline-based chemotherapy is a major cause of treatment failure for AML (AML) patients."],
        [2003, "Deoxycytidine kinase and cN-II nucleotidase expression in blast cells predict survival in AML patients treated with cytarabine."],
        [2008, "arsenictrioxide (As(2)O(3)) is an effective agent for the treatment of relapsed AML (APL)."],
        [2015, "This report shows our experience in 38 patients with AML treated with azacitidine or palliative treatment."],
        [2004, "In vitro cytotoxicity of mitoxantrone-incorporated albumin microspheres on AML cells."],
        [2003, "To detect the expression of cytokines by AML (APL) cells before and after exposure to arsenictrioxide."],
        [2014, "arsenictrioxide (arsenictrioxide) has been used in the treatment of AML (APL) and many malignant solid tumors."],
        [2019, "MALAT1 knockdown inhibits proliferation and enhances cytarabine chemosensitivity by upregulating miR-96 in AML cells."],
        [2000, "arsenictrioxide (arsenictrioxide)-treatment is effective in AML (APL) patients with t(15;17)."],
        [2020, "Venetoclax-based therapy can induce responses in approximately 70% of older previously untreated patients with AML (AML)."],
        [2009, "arsenictrioxide (arsenictrioxide) induces differentiation and apoptosis in AML (APL)."],
        [2002, "Compared with DS ALL, DS AML cells were significantly more sensitive to cytarabine only (21-fold)."],
        [2009, "The anti-leukaemic activity was assessed on NB4 AML cells (vs solutions of arsthinol, arsenictrioxide and melarsoprol)."],
        [1985, "doxorubicin and cytarabine contribute equally to prediction of response in AML with improved confidence level."],
        [1993, "Fludarabine potentiates metabolism of cytarabine in patients with AML during therapy."],
        [2006, "Currently, arsenictrioxide (arsenictrioxide) is considered the treatment of choice for patients with relapsed AML (APL)."],
        [2006, "We derived nine highly cytarabine-resistant murine BXH-2 strain AML sublines via in vitro selection."],
        [2016, "Hypomethylating drugs such as azacitidine are active in AML (AML) as monotherapy."],
        [2012, "Here, we investigated the possible role of miR-181a in AML cytarabine resistance."],
        [2022, "The cure rate for core-binding factor AML (AML) is 75% with fludarabine, high-dose cytarabine, and gemtuzumab-ozogamicin."],
        [1983, "Therapeutic responses included a partial remission in a patient with AML (AML) refractory to cytarabine."],
        [2018, "Intermediate-dose cytarabine plus mitoxantrone versus standard-dose cytarabine plus daunorubicin for AML in elderly patients."],
        [2022, "The pharmacokinetics of therapeutic arsenictrioxide in AML patients."],
        [2020, "Genomic markers of midostaurin drug sensitivity in FLT3 mutated and FLT3 wild-type AML patients."],
        [2007, "Reversible posterior leukoencephalopathy syndrome after repeat intermediate-dose cytarabine chemotherapy in a patient with AML."],
        [1997, "Altered intracellular distribution of daunorubicin in immature AML cells."],
        [2015, "Obatoclax potentiates the cytotoxic effect of cytarabine on AML cells by enhancing DNA damage."],
        [1992, "Thus, AML blasts respond to fazarabine in culture with a pattern similar to that of 5-aza and opposite to that of cytarabine."],
        [2022, "These results suggest that the ONO-7475/venetoclax combination may be effective for AML therapy."],
        [2006, "arsenictrioxide (As(2)O(3)) induces both the differentiation and apoptosis of AML cells in a concentration dependent manner."],
        [2020, "MicroRNA-33b regulates sensitivity to daunorubicin in AML by regulating eukaryotic translation initiation factor 5A-2."],
        [2018, "miR-134 increases the antitumor effects of cytarabine by targeting Mnks in AML cells."],
        [2016, "Randomized studies with gemtuzumab-ozogamicin have validated CD33 as a target for antigen-specific immunotherapy of AML (AML)."],
        [2019, "Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients."],
        [2008, "arsenictrioxide (arsenictrioxide) induces remission in 85% of adults with refractory AML (APL)."],
        [2011, "Combinations with arsenictrioxide, sorafenib, and cytarabine demonstrated synergistic in vitro effects in AML cell lines."],
        [2020, "Safety and Feasibility of Outpatient High Dose Cytarabine for AML in the Brazilian Amazon."],
        [2009, "The success of arsenictrioxide in the treatment of AML has renewed interest in the cellular targets of As(III) species."],
        [2003, "arsenictrioxide-induced mitotic arrest and apoptosis in AML cells."],
        [2020, "arsenictrioxide induces autophagic degradation of the FLT3-ITD mutated protein in FLT3-ITD AML cells."],
        [2018, "arsenictrioxide (TX) has been used in the treatment of both de novo and relapsed AML (APL) patients."],
        [2014, "Our study provides a novel clue that CD44 plays a significant role in the chemoresistance of AML cells to cytarabine and ADM."],
        [2018, "High-Risk AML with Unusual T/Myeloid Immunophenotype Successfully Treated with ATRA and arsenictrioxide-Based Regimen."],
        [1985, "Preliminary results in secondary AML (ANLL) treated with Idarubicin."],
        [2020, "All-Trans Retinoic Acid Synergizes with Enasidenib to Induce Differentiation of IDH2-Mutant AML Cells."],
        [2010, "Single cycle of arsenictrioxide-based consolidation chemotherapy spares anthracycline exposure in the primary management of AML."],
        [2015, "Idarubicin, cytarabine, and pravastatin as induction therapy for untreated AML and high-risk myelodysplastic syndrome."],
        [2013, "Arsenic methylation metabolism and liver injury of AML patients undergoing arsenictrioxide treatment."],
        [2018, "We analyzed 128 patients from two institutions with MDS or AML treated with azacitidine to identify prognostic indicators."],
        [1993, "Therapy of refractory/relapsed AML and blast crisis of chronic myeloid leukemia with the combination of cytarabine."],
        [2020, "Fatty acid metabolism underlies venetoclax resistance in AML stem cells."],
        [1996, "A prospective randomized trial of idarubicin vs daunorubicin in combination chemotherapy for AML of the age group 55 to 75."],
        [2017, "ERG amplification, the most frequent CNA, was related to cytarabine resistance, a cornerstone drug of AML therapy."],
        [2013, "Interestingly, angiocidin+cytosine arabinoside (cytarabine) combination therapy reduced human AML in bone marrow by 79%."],
        [2014, "Cytarabine plays a pivotal role in the treatment of patients with AML (AML)."],
        [2013, "Aquaporin 9, a promising predictor for the cytocidal effects of arsenictrioxide in AML cell lines and primary blasts."],
        [2005, "Cytarabine (cytarabine) is the most effective agent for the treatment of AML (AML)."],
        [2019, "Daunorubicin and mitoxantrone considered as crucial components of almost all standard AML induction regimens."],
        [2011, "The investigations involved 22 patients with AML undergoing chemotherapy with daunorubicin, cytarabine."],
        [1992, "We conclude that intermediate dose cytarabine did not substantially improve results of induction chemotherapy for AML."],
        [2012, "Effects of selective checkpoint kinase 1 inhibition on cytarabine cytotoxicity in AML cells in vitro."],
        [2014, "In conclusion, azacitidine may reinduce durable remissions in very few patients with AML or myelodysplastic syndrome."],
        [2003, "Antibody-targeted chemotherapy of AML using gemtuzumab-ozogamicin (gemtuzumab-ozogamicin)."],
        [2012, "Accordingly, further investigation of the cytarabine/SCH 900776 combination in AML appears warranted."],
        [2019, "Standard treatment for higher risk myelodysplastic syndromes, chronic myelomonocytic leukemia and low blast AML is azacitidine."],
        [2017, "Treatment for AML (AML) generally consists of a combination of cytarabine and an anthracycline."],
        [2017, "We report the first adult AML cohort in which the influence of these SNPs in cytarabine efficacy and toxicity was analyzed."],
        [2020, "Moreover, ectopic expression of miR-143 further decreases cell viability in cytarabine-treated AML cells."],
        [2000, "Recently, DNR has been replaced in many centers by idarubicin (IDA) as the first choice anthracycline in AML treatment."],
        [2017, "cytarabine-resistant AML cell lines were sensitive to BTZ and DSF/Cu2+."],
        [2004, "We studied the effect of herbimycin A, 6,7-dimethoxy-2-phenylquinoxaline and midostaurin on primary AML blasts."],
        [2000, "Forty-seven patients with recurrent or refractory AML were treated with cytarabine, 0.5 gm/m2, intravenously (i.v.)"],
        [1985, "The utility and indication for low-dose cytarabine therapy of AML remains to be determined."],
        [2018, "Comparison of induction therapy in non-high risk AML with arsenictrioxide or in combination with ATRA."],
        [2004, "High-dose intermittent cytarabine is an effective postremission treatment for patients with AML (AML)."],
        [2014, "Intensive chemotherapy with daunorubicin (daunorubicin) is associated with serious side effects in AML (AML) patients."],
        [1984, "Delayed growth arrest was observed in HL-60 AML cells after exposure to thioguanine (thioguanine)."],
        [2017, "arabinofuranosylcytosine (cytarabine) is a mainstay in the initial treatment of AML (AML), although relapses are common."],
        [2015, "Azacitidine/lenalidomide as maintenance therapy for high-risk AML warrants further exploration."],
        [2003, "arsenictrioxide (arsenictrioxide) is capable of inducing a high hematologic response rate in patients with relapsed AML (APL)."],
        [2007, "All trans-retinoic acid and arsenictrioxide have already demonstrated efficacy in AML in both adults and children."],
        [2019, "Midostaurin for the management of FLT3-mutated AML and advanced systemic mastocytosis."],
        [2018, "The current standard of care for the treatment of patients with newly diagnosed AML (AML) is an anthracycline plus cytarabine."],
        [1996, "Complete remission was obtained following standard chemotherapy for AML (doxorubicin, cytosin-arabinoside, thioguanine)."],
        [2020, "arsenictrioxide (arsenictrioxide) has been proved useful for the treatment of AML (APL)."],
        [2016, "The clinical use of arsenictrioxide (arsenictrioxide) for treating AML (APL) is limited due to its severe cardiotoxicity."],
        [2017, "Chidamide in FLT3-ITD positive AML and the synergistic effect in combination with cytarabine."],
        [2019, "Effect of combination of all-trans retinoic acid and arsenictrioxide on apoptosis of AML cells."],
        [2009, "Taken together, these findings demonstrate that dCK can regulate the in vitro cellular response to cytarabine in AML cells."],
        [2019, "Factors affecting thrombohemorrhagic early death in patients with AML treated with arsenictrioxide alone."],
        [2004, "Early occurrence of AML following adjuvant radiotherapy and higher cumulative dose of cyclophosphamide in carcinoma breast."],
        [2007, "Arsenic in the cerebrospinal fluid of a patient receiving arsenictrioxide for relapsed AML with CNS involvement."],
        [2015, "arsenictrioxide has been successfully used for the treatment of patients with AML (APL) worldwide."],
        [2020, "Disulfiram/cytarabine eradicates a subset of AML stem cells with high aldehyde dehydrogenase expression."],
        [2019, "Toward Candidate Proteomic Biomarkers in Clinical Monitoring of AML Treatment with arsenictrioxide."],
        [2015, "Retinoic acid and arsenictrioxide trigger degradation of mutated NPM1, resulting in apoptosis of AML cells."],
        [1996, "All patients with relapsed or persistent AML had been pretreated with idarubicin and cytarabine."],
        [2021, "Azacitidine for the treatment of patients with relapsed AML after allogeneic stem cell transplantation."],
        [1994, "Cytarabine (cytarabine) is currently used in the treatment of adult AML (AML)."],
        [2018, "Midostaurin (midostaurin) is being investigated for the treatment of AML (AML) and advanced systemic mastocytosis (advSM)."],
        [1986, "A comparison of in vitro sensitivity of AML precursors to mitoxantrone, 4'deoxydoxorubicin, idarubicin and daunorubicin."],
        [2018, "Synergistic suppression effect on tumor growth of AML by combining cytarabine with an engineered oncolytic vaccinia virus."],
        [2016, "and abrogated resistance to cytarabine in AML cells cocultured with HS-5 stromal cells."],
        [2018, "Cytarabine has been an integral part of AML (AML) chemotherapy for over four decades."],
        [2018, "Retinoic acid and arsenictrioxide sensitize AML cells to ER stress."],
        [2022, "Real-World Experience of Measurable Residual Disease Response and Prognosis in AML Treated with Venetoclax and Azacitidine."],
        [2013, "PI-103 sensitizes AML stem cells to daunorubicin-induced cytotoxicity."],
        [2008, "Acute intestinal pseudo-obstruction after induction treatment of relapsed AML with arsenictrioxide."],
        [2013, "azacitidine and lenalidomide both have meaningful single-agent clinical activity in HR-MDS and AML with del(5q)."],
        [1993, "This led us to administer fludarabine and cytarabine to 59 patients with AML in relapse or unresponsive to initial therapy."],
        [2011, "This study was designed to examine the role of autophagy in the death of human AML NB4 cells initiated by arsenictrioxide."],
        [1999, "Acute pancreatitis in AML (AML) has been rarely associated with cytarabine therapy."],
        [2021, "Deoxycytidine Kinase (DCK) Mutations in Human AML Resistant to Cytarabine."],
        [2014, "Adding ascorbic acid to arsenictrioxide produces limited benefit in patients with AML excluding AML."],
        [2021, "One could reasonably expect other subsets of AML to benefit from this regimen or other applications of venetoclax combinations."],
        [2015, "high-dose cytarabine therapy followed by allo-HSCT could improve the prognosis of MK-positive AML patients."],
        [2019, "Post-Myelofibrosis AML Effectively Treated with a Combination of Ruxolitinib and azacitidinecytidine."],
        [2019, "Topoisomerase inhibitor mitoxantrone was the least effective drug against NUP98-NSD1+/FLT3-ITD+ AML cells."],
        [1996, "Steady progress has been made in the treatment of AML since the discovery of daunorubicin in the 1960s."],
        [2018, "The proportion of patients with AML (AML) cured is increased by administering high-dose cytarabine (HiDAC)."],
        [2002, "arsenictrioxide has shown substantial efficacy in treating both newly diagnosed and relapsed patients with AML (APL)."],
        [2020, "MicroRNA-143 sensitizes AML cells to cytarabine via targeting ATG7- and ATG2B-dependent autophagy."],
        [2010, "arsenictrioxide (As(2)O(3)) is widely used to treat AML (APL)."],
        [1999, "Pancreatitis in the setting of AML therapy may be an infrequent and self-limited toxicity of cytarabine."],
        [2021, "We report 7 relapsed/refractory (R/R) AML (AML) patients treated with venetoclax and hypomethylating agents (HMA)."],
        [2018, "Cytarabine (cytarabine) is the backbone of AML (AML) chemotherapy."],
        [2021, "arsenictrioxide [ATO, inorganic arsenite (iAsIII) in solution] plays an important role in the treatment of AML (APL)."],
        [2011, "arsenictrioxide (arsenictrioxide) treatment induces clinical remission in AML patients."],
        [2003, "The interaction of daunorubicin and mitoxantrone with the red blood cells of AML patients."],
        [2021, "Oral arsenictrioxide (arsenictrioxide) has demonstrated a favorable clinical efficiency in the treatment of AML (APL)."],
        [2018, "Comprehensive cytarabine SNP score predicts leukemic cell intracellular ara-CTP levels in pediatric AML patients."],
        [2015, "We previously reported that FLT3-ITD confers resistance to cytarabine (cytarabine), a key cytotoxic agent in AML treatments."],
        [1972, "Fourty-four patients with AML were treated with RP 22050, a new, semisynthetic derivative of daunorubicin."],
        [1991, "Growth factors also affect the sensitivity of AML blast cells to cytarabine (cytarabine)."],
        [2002, "arsenictrioxide (arsenictrioxide) has been reported to be a safe and effective treatment for relapsed AML (APL)."],
        [2013, "Monosomal karyotype improves IPSS-R stratification in MDS and AML patients treated with Azacitidine."],
        [1970, "Combination chemotherapy using L-asparaginase, daunorubicin, and cytarabine in adults with AML."],
        [2021, "CD44 loss of function sensitizes AML cells to the BCL-2 inhibitor venetoclax by decreasing CXCL12-driven survival cues."],
        [2021, "Venetoclax combines synergistically with FLT3 inhibition to effectively target leukemic cells in FLT3-ITD+ AML models."],
        [1989, "The urine of a patient who suffered from AML was red coloured after administration of mitoxantrone and etoposid."],
        [2019, "Knockdown of MALAT1 inhibited the proliferation, induced apoptosis, and enhanced cytarabine sensitivity of AML cells."],
        [2004, "Arsenic speciation in urine from AML patients undergoing arsenictrioxide treatment."],
        [2021, "We report here that cytarabine (cytarabine) treatment elevates DANCR expression in human AML cells."],
        [2008, "gemtuzumab-ozogamicin (gemtuzumab-ozogamicin) is effective as single agent in the treatment of AML (AML)."],
        [1993, "Infusion of fludarabine before cytarabine augments the rate of ara-CTP synthesis in circulating AML blasts during therapy."],
        [2017, "Long-term outcome of AML treated with all-trans-retinoic acid, arsenictrioxide, and gemtuzumab."],
        [2021, "The hypomethylating agents (HMA) decitabine and azacitidine are used in AML (AML) for induction therapy in select patients."],
        [1988, "In vivo uptake of daunorubicin by AML (AML) cells measured by flow cytometry."],
        [2019, "Cytarabine (cytarabine) is a nucleoside analog used in the treatment of AML (AML)."],
        [1988, "A case of persistent cerebellar dysfunction following high-dose cytarabine (cytarabine) treatment of AML is reported."],
        [2021, "KDM4C contributes to cytarabine resistance in AML via regulating the miR-328-3p/CCND2 axis through MALAT1."],
        [1988, "Daunorubicin in patients with relapsed and refractory AML previously treated with anthracycline."],
        [2019, "Thus, curcumin and tetrahydrocurcumin have potential applications in the treatment of AML with cytarabine resistance."],
        [2006, "Cross-resistance to cytarabine in human AML cells selected for resistance to vincristine."],
        [2015, "Unusual massive bone marrow fibrosis in AML following arsenictrioxide therapy."],
        [2019, "High-dose cytarabine is the backbone of AML (AML) treatment."],
        [2009, "Cytarabine (cytarabine) is the key agent for treating AML (AML)."],
        [2011, "arsenictrioxide (arsenictrioxide) was successfully used in the treatment of AML (APL) etc."],
        [2016, "arsenictrioxide (As(III) in solution) has been shown to be the most active single agent in combating AML (APL)."],
        [2015, "azacitidine may be an important treatment option for this difficult-to-treat AML population."],
        [2016, "Inhibition of Mnk enhances apoptotic activity of cytarabine in AML cells."],
        [1988, "Interleukin 3 enhances the cytotoxic activity of cytarabine (cytarabine) on AML (AML) cells."],
        [2012, "arsenictrioxide (arsenictrioxide) has been successfully used as a treatment for AML (APL) for more than a decade."],
        [2017, "cytarabine (cytarabine) is one of the key drugs for treating AML (AML)."],
        [2013, "arsenictrioxide (arsenictrioxide) shows substantial anticancer activity in patients with AML (APL)."],
        [1998, "Seven relapsed and/or refractory AML patients were treated by arsenictrioxide (arsenictrioxide)."],
        [2021, "Moreover, combination of Tomivosertib and Venetoclax resulted in synergistic anti-leukemic responses in AML cell lines."],
        [2009, "arsenictrioxide has been used as a therapeutic agent for AML and recently for some solid tumors."],
        [1978, "Normal infant after treatment of AML in pregnancy with daunorubicin."],
        [2019, "Induction schedules in AML (AML) are based on combinations of cytarabine and anthracyclines."],
        [2003, "arsenictrioxide (As(2)O(3)) is an effective treatment for AML (APL), but is less effective against other leukemias."],
        [2011, "Notable success was observed in the treatment of AML (APL) with arsenictrioxide (arsenictrioxide)."],
        [2018, "Our results demonstrated that GLUT3 plays a fundamental role in the survival and resistance of AML cells to vincristine."],
        [2021, "These data confirm the efficacy and safety of vyxeos in high-risk AML (t-AML and MRC-AML) in a real-life setting."],
        [2016, "miR-29c is of prognostic value and influences response to azacitidine treatment in older AML patients."],
        [2002, "We report a patient with AML who developed fulminant rhabdomyolysis after treatment with a cytarabine-containing regimen."],
        [1993, "A young patient with AML was treated with high-dose cytarabine (3.0 g/m2 every 12 hours)."],
        [2021, "The combination effects of ST1326 and venetoclax were studied in AML cells and primary patients."],
        [2015, "Azacitidine access program for Belgian patients with myelodysplastic syndromes, AML or chronic myelomonocytic leukemia."],
        [1989, "Eight patients with AML were treated with a combination of daunorubicin (1.5 mg/kg body weight) and cytarabine."],
        [2021, "Analysis of gamma-glutamyltransferase in AML patients undergoing arsenictrioxide treatment."],
        [2022, "BCL-2 inhibition has been shown to be effective in AML (AML) in combination with hypomethylating agents or low-dose cytarabine."],
        [2019, "With the introduction of arsenictrioxide and all-trans retinoic acid, the prognosis of AML has greatly improved."],
        [2014, "ABT-737, Synergistically Enhances Daunorubicin-Mediated Apoptosis in AML Cell Lines."],
        [2016, "mitoxantrone and Etoposide for the Treatment of AML Patients in First Relapse."],
        [2008, "All-trans-retinoic acid (ATRA) and arsenictrioxide (arsenictrioxide) induce differentiation and apoptosis in AML (APL) cells."],
        [2018, "Emodin and Its Combination with Cytarabine Induce Apoptosis in Resistant AML Cells in Vitro and in Vivo."],
        [2021, "Midostaurin was registered in combination with chemotherapy to treat newly diagnosed AML."],
        [1984, "The current status of, and the future prospects for, low-dose cytarabine therapy in patients with AML is discussed."],
        [2002, "Synergic effects of arsenictrioxide and cAMP during AML cell maturation subtends a novel signaling cross-talk."],
        [2012, "Feasibility of azacitidine added to standard chemotherapy in older patients with AML--a randomised SAL pilot study."],
        [2018, "arsenictrioxide (arsenictrioxide) has a dramatic therapeutic effect on AML (APL) patients."],
        [1981, "Sequential combination of pyrazofurin and azacitidine in patients with AML and carcinoma."],
        [2019, "To date, the first-line treatment of AML is still based on daunorubicin and cytarabine or idarubicin and cytarabine regimen."],
        [2011, "Treatment of AML cells, that have RIZ1 methylation, with azacitidine-dC, induced growth suppression with RIZ1 restoration."],
        [2005, "Daunorubicin (daunorubicin) is commonly used to treat AML (AML)."],
        [2021, "Targeting NF-κB-dependent alkaliptosis for the treatment of venetoclax-resistant AML cells."],
        [2008, "In AML and APL cell lines, but not primary patient samples, basal catalase levels matched sensitivity to arsenictrioxide."],
        [2017, "Sorafenib and azacitidine as salvage therapy for relapse of FLT3-ITD mutated AML after allo-SCT."],
        [2002, "Atypical blasts and bone marrow necrosis associated with near-triploid relapse of AML after arsenictrioxide treatment."],
        [2015, "Budgetary impact of treating AML patients with first-line arsenictrioxide and retinoic acid from an Italian payer perspective."],
        [2006, "arsenictrioxide (arsenictrioxide) is a potent antitumor agent used to treat AML (APL) and, more recently, solid tumors."],
        [2021, "Successful treatment of AML in a patient undergoing hemodialysis with arsenictrioxide."],
        [1986, "A case of persistent cerebellar toxicity following systemic high dose cytarabine (HDCA) treatment of AML is reported."],
        [2019, "The BCL-2 inhibitor venetoclax demonstrated activity as monotherapy and in combination with chemotherapy or HMA in AML."],
        [2022, "Venetoclax synergizes with Gilteritinib in FLT3 wildtype high-risk AML by suppressing MCL-1."],
        [2001, "arsenictrioxide has been shown to be effective in treating AML (APL), with minimal overall toxicity reported to date."],
        [1995, "An effective salvage regimen with aclarubicin for daunorubicin-resistant AML in children."],
        [2022, "Azacitidine maintenance in AML post induction and posttransplant."],
        [2017, "combination effects of arsenictrioxide and sorafenib in two AML cell lines, KG-1 and U937."],
        [2018, "Combined treatment with a PARP inhibitor and daunorubicin had an additive effect on the killing of IDH1/2MUT AML cells."],
        [2018, "Daunorubicin and Cytarabine Liposome in Newly Diagnosed Therapy-Related AML (AML) or AML With Myelodysplasia-Related Changes."],
        [2010, "Today, arsenictrioxide is used as one of the standard therapies for AML (APL)."],
        [2002, "High-dose cytarabine as consolidation treatment for patients with AML with t(8;21)."],
        [2001, "Chemotherapy for treatment of AML with fludarabine, cytarabine."],
        [2019, "Midostaurin added to intensive chemotherapy is approved in FLT3-mutated AML."],
        [2013, "azacitidinecytidine treatment for relapsed or refractory AML after intensive chemotherapy."],
        [2021, "EVs derived from both new cases and relapsed AML patients significantly reduced idarubicin-induced apoptosis in the U937 cells."],
        [2009, "arsenictrioxide may reduce hyperfibrinolysis in AML by downregulation of Ann II."],
        [2018, "Similarly for IGF1R, knockdown increased the cytarabine sensitivity of AML cell lines consistent with results in AML patients."],
        [2022, "Acquired genetic mutations can confer resistance to arsenictrioxide (arsenictrioxide) in the treatment of AML (APL)."],
        [2011, "Fludarabine and cytarabine in patients with AML refractory to two different courses of front-line chemotherapy."],
        [2019, "Nucleoside analog, cytarabine (cytarabine) is the mainstay of AML (AML) chemotherapy."],
        [2020, "The AML cells overexpressing hsa-miR-12462 had increased sensitivity to cytarabine chemotherapy."],
        [2022, "Measurable Residual Disease Response and Prognosis in Treatment-Naïve AML With Venetoclax and Azacitidine."],
        [2021, "Impact of splicing mutations in AML treated with hypomethylating agents combined with venetoclax."],
        [2015, "azacitidine seems a reasonable therapeutic option for most unfit AML patients, i.e."],
        [2011, "The efficacy of arsenictrioxide (arsenictrioxide) against AML (APL) and relapsed APL has been well documented."],
        [2001, "Sudden death among patients with AML treated with arsenictrioxide."],
        [2009, "Defective expression of deoxycytidine kinase in cytarabine-resistant AML cells."],
        [2008, "To evaluate the contribution of an autophagic mechanism to the arsenictrioxide- induced death of human AML cell line HL60 cells."],
        [2019, "Cost Effectiveness of Midostaurin in the Treatment of Newly Diagnosed FLT3-Mutated AML in the United States."],
        [2021, "It induced the DNA damage response kinase WEE1, and rendered human AML cell lines more resistant to cytarabine."],
        [2002, "arsenictrioxide promotes histone H3 phosphoacetylation at the chromatin of CASPASE-10 in AML cells."],
        [2017, "Disulfiram overcomes bortezomib and cytarabine resistance in Down-syndrome-associated AML cells."],
        [2016, "Cytarabine (cytarabine) is a first line clinical therapeutic agent for treatment of AML (AML)."],
        [2016, "cytarabine, sorafenib) in all tested AML cell lines regardless of their FLT3 mutation status."],
        [2021, "Venetoclax-based combinations in AML and high-risk MDS prior to and following allogeneic hematopoietic cell transplant."],
        [2007, "To investigate the long-term outcome of idarubicin- and cytarabine-based intensive chemotherapy in adult AML (AML)."],
        [2002, "arsenictrioxide (As(2)O(3)) has been found effective in the treatment in the treatment of AML (APML)."],
        [2002, "Samples with chromosome 5/7 abnormalities were median 3.9-fold (P =.01) more resistant to cytarabine than other AML samples."],
        [2017, "Causes and prognostic factors for early death in patients with AML treated with single-agent arsenictrioxide."],
        [1986, "Patients with AML received cytarabine, either 2 or 6 g/m2/72 h by continuous infusion."],
        [2018, "arsenictrioxide and Sorafenib Induce Synthetic Lethality of FLT3-ITD AML Cells."],
        [1987, "Etoposide in combination with cytarabine, doxorubicin, and thioguanine for treatment of AML in a protocol adjusted for age."],
        [2018, "arsenictrioxide (arsenictrioxide) is successfully used as an anticancer agent against AML and some solid tumors."],
        [2021, "azacitidine (azacitidine) is a standard of care for higher-risk myelodysplastic syndrome (MDS)/low blast-count AML (AML)."],
        [2017, "In patients with AML and FA, azacitidine can be considered an alternative to conventional chemotherapy."],
        [2018, "arsenictrioxide Enhances the NK Cell Cytotoxicity Against AML While Simultaneously Inhibiting Its Bio-Genesis."],
        [2022, "Combination strategies to promote sensitivity to cytarabine-induced replication stress in AML with and without DNMT3A mutations."],
        [2014, "Azacitidine as salvage therapy for AML in a severely ill patient."],
        [2015, "Inhibition of PI3K can restore cytarabine sensitivity of AML blasts at hypoxic conditions."],
        [2017, "Azacitidine or intensive chemotherapy for older patients with secondary or therapy-related AML."],
        [2021, "Cytarabine and daunorubicin are old drugs commonly used in the treatment of AML (AML)."],
        [2016, "Exceptions in patterns of arsenic compounds in urine of AML patients treated with arsenictrioxide."],
        [2018, "arsenictrioxide (arsenictrioxide) is used in the clinic for the treatment of AML by targeting the protein PML."],
        [2018, "Cytarabine arabinoside (cytarabine) has been the core of chemotherapy for adult AML (AML)."],
        [2019, "HMGA2 regulates AML progression and sensitivity to daunorubicin via Wnt/β-catenin signaling."],
        [2000, "Growth and endocrine function in children with AML after bone marrow transplantation using busulfan/cyclophosphamide."],
        [2018, "arsenictrioxide enhance reactive oxygen species levels and induce apoptosis and suppresses proliferation in AML cells."],
        [2010, "Cytarabine resistance characterizes relapsed and refractory AML (AML)."],
        [2020, "HL-60 human AML cells were used to develop the cytarabine- or clofarabine (CAFdA)-resistant variants."],
        [2021, "Mechanisms for resistance in AML insights into molecular pathways mediating resistance to venetoclax."],
        [2015, "In total, 263 Chinese intermediate-risk AML patients treated with anthracycline and cytarabine were enrolled."],
        [2000, "Hemostatic abnormalities associated with AML and corrective effects of all-trans-retinoic acid or arsenictrioxide treatment."],
        [2009, "Resistance to cytarabine (cytarabine) incapacitates the therapeutic effort during the treatment of AML (AML)."],
        [2021, "Successful bridge therapy of gilteritinib to cord blood transplantation in relapsed AML after bone marrow transplantation."],
        [2013, "The HSP90 inhibitor NVP-AUY922-AG inhibits the PI3K and IKK signalling pathways and synergizes with cytarabine in AML cells."],
        [2014, "Knockdown of CD44 enhances chemosensitivity of AML cells to ADM and cytarabine."],
        [2007, "Combined low-dose cytarabine, melphalan and mitoxantrone for older patients with AML or high-risk myelodysplastic syndrome."],
        [2015, "To highlight the acceptable results seen after use of low dose cytarabine in elderly patients of AML (AML) with comorbidities."],
        [2000, "P-glycoprotein in primary AML and treatment outcome of idarubicin/cytosine arabinoside-based induction therapy."],
        [2011, "arsenictrioxide (arsenictrioxide) is used in patients with AML and is active in vitro in several solid tumor cell lines."],
        [2011, "Use of cytarabine and idarubicin in a newly diagnosed AML patient with a severe wound."],
        [2022, "venetoclax/venetoclax potentiates the cytotoxicity of alkylating agents and fludarabine in AML cells."],
        [2016, "Furthermore, glasdegib sensitized AML cells to cytarabine."],
        [2021, "Resistance to cytarabine is an important cause of therapy failure in persons with AML (AML)."],
        [2019, "Midostaurin offers a novel strategy to treat both FLT3-mutated AML and advanced SM."],
        [2000, "arsenictrioxide (arsenictrioxide) was recently identified as a very potent agent against AML (APL)."],
        [2002, "Antibody-targeted chemotherapy of older patients with AML in first relapse using gemtuzumab-ozogamicin (gemtuzumab-ozogamicin)."],
        [1996, "We evaluated the role of ABMT in late 1st CR AML adult patients using busulfan plus cyclophosphamide as preparative regimen."],
        [2015, "Daunorubicin and cytarabine has been the standard-of-care for induction therapy for AML (AML)."],
        [2021, "Venetoclax, combined with hypomethylating agents, seems to be an effective option for young relapsed/refractory AML patients."],
        [2014, "Prognostic value of TP53 gene mutations in myelodysplastic syndromes and AML treated with azacitidine."],
        [1976, "Maintenance of remission in adult AML using intermittent courses of cytarabine (cytarabine) and thioguanine (thioguanine)."],
        [2015, "A patient treated with cyclophosphamide due to vasculitis, subsequently developed AML months after treatment."],
        [2013, "Determination of arsenic metabolites in patients with newly diagnosed AML treated with arsenictrioxide."],
        [2000, "arsenictrioxide has recently been used in the treatment of both relapsed and de novo AML (APML)."],
        [2012, "Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with AML (AML)."],
        [2006, "In vitro synergy of irinotecan followed by cytarabine was confirmed in a human AML cell line as a basis for the clinical trial."],
        [2014, "arsenictrioxide (arsenictrioxide) is presently the most active single agent in the treatment of AML (APL)."],
        [2010, "PURPOSE In patients with AML (AML), induction chemotherapy is based on standard doses of anthracyclines and cytarabine."],
        [2022, "A novel polyethylene glycol (PEG)-drug conjugate of Venetoclax, a Bcl-2 inhibitor, for treatment of AML (AML)."],
        [2010, "Mosaic Down syndrome-associated AML does not require high-dose cytarabine treatment for induction and consolidation therapy."],
        [2009, "arsenictrioxide is already used clinically to treat AML demonstrating its safety profile."],
        [2011, "Conversely, arsenictrioxide (AsTO) has successfully been employed in the treatment of AML (APL)."],
        [2013, "The efficacy of arsenictrioxide (arsenictrioxide) in the treatment of AML (APL) is widely accepted."],
        [2017, "Preclinical data have suggested synergy in vitro between cytarabine and imatinib mesylate (IM) on AML cell growth inhibition."],
        [2002, "Development of resistance to cytarabine (cytarabine) is a major problem in the treatment of patients with AML (AML)."],
        [2018, "CDA as a predictive marker for life-threatening toxicities in patients with AML treated with cytarabine."],
        [2019, "Chidamide Enhances the Cytotoxicity of Cytarabine and Sorafenib in AML Cells by Modulating H3K9me3 and Autophagy Levels."],
        [2021, "225Ac-labeled CD33-targeting antibody reverses resistance to Bcl-2 inhibitor venetoclax in AML models."],
        [2018, "The dose escalation of cytarabine in induction therapy lead to improved remission rates in the elderly AML patients."],
        [2018, "Similarly, samples collected from patients with AML treated with midostaurin showed a reduction in Tregs markers."],
        [1999, "arsenictrioxide selectively induces AML cell apoptosis via a hydrogen peroxide-dependent pathway."],
        [2001, "Successful treatment of a case of relapsed AML with arsenictrioxide."],
        [2009, "Inhibition of MEK signaling enhances the ability of cytarabine to induce growth arrest and apoptosis of AML cells."],
        [2012, "Combination of cytarabine and topotecan in patients treated for AML with persistent disease after frontline induction."],
        [2013, "The anti-tumor effects of arsenictrioxide (arsenictrioxide) were well established in AML, but not in renal cell carcinoma (RCC)."],
        [2004, "The combination of fludarabine, cytarabine (cytarabine) and G-CSF (FLAG) is routinely used in the treatment of AML (AML)."],
        [2017, "Histone deacetylase inhibitors reduce differentiating osteoblast-mediated protection of AML cells from cytarabine."],
        [2022, "Downregulation of MSK1 enhanced the sensitivity of AML cells to cytarabine."],
        [2003, "Multiple complete remissions in a patient with AML (M4eo) with low-dose cytarabine and all-trans retinoic acid."],
        [2014, "We aimed to examine the role of 14-3-3ζ in AML chemosensitivity using HL-60 and vincristine-resistant HL-60/VCR cells."],
        [2021, "High dose cyclophosphamide for cytoreduction in patients with AML with hyperleukocytosis or leukostasis."],
        [1994, "Detection of cytarabine resistance in patients with AML using flow cytometry."],
        [2021, "Hotspot DNMT3A mutations in clonal hematopoiesis and AML sensitize cells to azacitidine via viral mimicry response."],
        [2015, "Expression of P-gp in AML and the reversal function of arsenictrioxide on drug resistance."],
        [2006, "Results of treatment of AML and myelodysplastic syndrome with etoposide, thioguanine, cytarabine (ETC) in elderly patients."],
        [1998, "Inv(16) AML cells show an increased sensitivity to cytarabine in vitro."],
        [2014, "cAMP protects AML cells from arsenictrioxide-induced caspase-3 activation and apoptosis."],
        [2022, "ONO-7475 synergizes with venetoclax to potently kill FLT3-mutant AML cell lines and primary cells."],
        [2012, "Moreover, we were able to show that JQ1 synergizes with cytarabine in inducing growth inhibition in AML cells."],
        [2008, "BMSCs were found to maintain cytarabine-exposed primary AML cells by protection against spontaneous apoptosis."],
        [2012, "Combination therapy with arsenictrioxide, all-trans retinoic acid, and chemotherapy in AML patients with various relapse risks."],
        [2015, "arsenictrioxide (arsenictrioxide) is an effective drug used in AML (AML)."],
        [1987, "Four patients with AML (AML) and three with myelodysplastic syndrome (MDS) were given low dose cytarabine (cytarabine) therapy."],
        [2016, "By targeting MCL-1 and BCL-XL, resistant AML cell lines could be resensitized to venetoclax."],
        [2019, "The histone deacetylase (HDAC) inhibitor panobinostat potentiates anthracycline and cytarabine cytotoxicity in AML (AML) cells."],
        [2018, "Influence of UGT1A1 polymorphisms on the outcome of AML patients treated with cytarabine-base regimens."],
        [2015, "MK-2206 induces apoptosis of AML cells and enhances the cytotoxicity of cytarabine."],
        [2019, "The recommended dose of midostaurin is 50 mg orally twice daily for AML and 100 mg orally twice daily for ASM, SM-AHN and MCL."],
        [2016, "Clinical response to azacitidine therapy depends on microRNA-29c (miR-29c) expression in older AML (AML) patients."],
        [2005, "arsenictrioxide (arsenictrioxide) and MEK1 inhibition synergize to induce apoptosis in AML cells."],
        [2017, "cytarabine (cytarabine) remains the backbone of most treatment regimens for AML (AML)."],
        [1982, "Relapses in nine patients with AML were treated with a combination of aclarubicin (ACR) and cytarabine (cytarabine)."],
        [2019, "To investigate the effect of apatinib combined with cytarabine on AML (AML) HL60 cells and its relevant mechanisms."],
        [1995, "Inhibition of bcl-2 with antisense oligonucleotides induces apoptosis and increases the sensitivity of AML blasts to cytarabine."],
        [1999, "dexamethasone does not counteract the response of AML cells to all-trans retinoic acid."],
        [2007, "Induction of complete remission in a patient with AML refractory to high-dose chemotherapy through treatment with azacitidine."],
        [2004, "mitoxantrone (MTZ) has been shown to be effective in the treatment of newly diagnosed AML (AML)."],
        [2009, "Blockade of MEK signaling potentiates azacitidine-2'-deoxycytidine-induced apoptosis and upregulation of p21(waf1) in AML cells."],
        [2003, "A combination of an anthracycline and cytarabine (cytarabine) is the core of most AML induction regimens."],
        [1998, "To date, the prognostic impact of cytarabine dose escalation within various cytogenetic groups of AML has not been assessed."],
        [2015, "The drug-resistant AML cell line HL-60R was significantly less sensitive to cytarabine and daunorubicin than HL-60 cells."],
        [2009, "Patients diagnosed with AML (AML) often receive cytarabine-based chemotherapy as standard treatment."],
        [2019, "These results suggest that gilteritinib has therapeutic potential in FLT3-mutated AML patients with FL overexpression."],
        [2010, "This study aimed to investigate the effects of arsenictrioxide (As(2)O(3)) on the mitochondrial DNA (mtDNA) of AML (APL) cells."],
        [2001, "Chemotherapy for AML in the elderly with cytarabine, mitoxantrone, and granulocyte-macrophage colony-stimulating factor."],
        [1987, "Fifteen patients with AML were given a total of 17 courses of high-dose cytarabine (cytarabine)."],
        [2019, "Evaluation of gilteritinib in combination with chemotherapy in preclinical models of FLT3-ITD+ AML."],
        [2016, "Three patients with high-grade myelodysplastic syndrome or AML who received azacitidine."],
        [2009, "To report a case of isolated hyperbilirubinemia in a patient treated with cytarabine-based chemotherapy for AML."],
        [1998, "Frequency of prolonged remission duration after high-dose cytarabine intensification in AML varies by cytogenetic subtype."],
        [2008, "arsenictrioxide (arsenictrioxide) is used clinically to treat AML but is less successful in other malignancies."],
        [2018, "Twenty patients with primary AML had been randomized into busulfan/fludarabine and modified busulfan/cyclophosphamide groups."],
        [2020, "Cytogenetics and mutations could predict outcome in relapsed and refractory AML patients receiving BCL-2 inhibitor venetoclax."],
        [2015, "arsenictrioxide (arsenictrioxide) is an approved treatment for AML (APL)."],
        [2007, "arsenictrioxide (arsenictrioxide) has demonstrated effectiveness in treating AML (APL)."],
        [2019, "arsenictrioxide and all-trans retinoic acid have become the frontline treatments for patients with AML (APL)."],
        [2014, "arsenictrioxide (arsenictrioxide) is a highly effective agent for the treatment of AML (APL)."],
        [2017, "Our findings are consistent with clinical data, in which vyxeos activity is retained in high-risk AML patients."],
        [2017, "arsenictrioxide (arsenictrioxide) has been verified as a breakthrough in the management of AML in recent decades."],
        [2019, "Daunorubicin (Dnr) is at the forefront of AML (AML) therapy, but drug resistance poses a major threat to treatment success."],
        [2012, "Over 80% of AML patients express CD33, a target of gemtuzumab-ozogamicin (gemtuzumab-ozogamicin)."],
        [2012, "The azacitidine/ABT-737 combination synergistically induced apoptosis in AML cells in seven of eight patients."],
        [2015, "arsenictrioxide is an effective and potent antitumor agent used in patients with AML and produces dramatic remissions."],
        [1990, "Treatment of poor-prognosis, newly diagnosed AML with high-dose cytarabine (cytarabine) and rHUGM-CSF."],
        [2000, "Respiratory failure during induction chemotherapy for AML (FAB M4Eo) with cytarabine and all-trans retinoic acid."],
        [1997, "Natural resistance of AML cell lines to mitoxantrone is associated with lack of apoptosis."],
        [2005, "The efficacy of All-Trans Retinoic Acid (Atra) and arsenictrioxide (As(2)O(3)) in the treatment of AML (APL) is well known."],
        [2020, "Cytarabine is the backbone of AML therapy, but the dose used during induction has remained controversial."],
        [2020, "Nicotinamide Metabolism Mediates Resistance to Venetoclax in Relapsed AML Stem Cells."],
        [2018, "At present, AML (APL) is the most curable form of AML and can be treated using all-trans retinoic acid and arsenictrioxide."],
        [2014, "CNS Involvement in AML Patient Treated with azacitidinecytidine."],
        [2010, "It is revealed that arsenictrioxide aggravates mtDNA mutation in the D-loop region of AML cells both in vitro and in vivo."],
        [2008, "Inorganic arsenictrioxide (As(2)O(3)) is a highly effective treatment for AML (APL)."],
        [1990, "Schedule-dependent interaction of cytarabine plus doxorubicin or cytarabine plus mitoxantrone in AML cells in culture."],
        [2018, "We examined the role of TET-FOXP3 axis in the cytotoxic effects of arsenictrioxide on the human AML cell line, U937."],
        [2018, "The ectopic expression of hTERT significantly attenuated the apoptotic effect of midostaurin on AML cells."],
        [2017, "Standard remission induction chemotherapy consisting of anthracycline plus cytarabine (3+7) is administered for adult AML (AML)."],
        [2016, "Successful use of high-dose cytarabine in a patient with AML and severe hepatic dysfunction."],
        [2019, "Increasingly, AML (APL) is treated with a combination of all-trans retinoic acid (ATRA) and arsenictrioxide (arsenictrioxide)."],
        [2019, "Bone Marrow Findings in Patients With AML Treated With arsenictrioxide."],
        [2019, "Apatinib enhances chemosensitivity of AML hl60 cells to cytarabine by inducing apoptosis."],
        [2015, "Prognostic factors of patients with newly diagnosed AML treated with arsenictrioxide-based frontline therapy."],
        [2009, "The management of prolonged, isolated hyperbilirubinemia following cytarabine-based chemotherapy for AML."],
        [2019, "miR-9 Enhances the Chemosensitivity of AML Cells to Daunorubicin by Targeting the EIF5A2/MCL-1 Axis."],
        [2015, "High dose cytarabine, mitoxantrone and l-asparaginase (HAMA) salvage for relapsed or refractory AML (AML) in the elderly."],
        [1998, "Treatment of AML in the older patient with attenuated high-dose cytarabine."],
        [2008, "The value of oral cytarabine ocfosfate and etoposide in the treatment of refractory and elderly AML patients."],
        [2012, "Arsenic in the form of arsenictrioxide (arsenictrioxide) is used as a therapeutic drug for treatment of AML (APL)."],
        [2010, "Daunorubicin (daunorubicin) is one of the anthracycline anti-tumor agents widely used in the treatment of AML."],
        [2012, "arsenictrioxide induces depolymerization of microtubules in an AML cell line."],
        [2017, "Enasidenib induces AML cell differentiation to promote clinical response."],
        [2004, "LDL increments were not correlated with cholesterol increments in cytarabine-treated AML samples."],
        [2012, "BCL2L10 is a predictive factor for resistance to azacitidine in MDS and AML patients."],
        [2017, "The combination of an anthracycline and cytarabine has been the standard induction therapy for AML for more than 3 decades."],
        [2007, "arsenictrioxide (arsenictrioxide, arsenictrioxide) is used to treat patients with refractory or relapsed AML (APL)."],
        [2012, "In vivo, FdUMP[10] was active against a syngeneic AML model with a survival advantage equivalent to doxorubicin plus cytarabine."],
        [2003, "gemtuzumab-ozogamicin has moderate activity as a single agent in patients with CD33-positive refractory or relapsed AML (AML)."],
        [2017, "Induction treatment of AML in an elderly patient with intramarrow injection/administration of cytarabine."],
        [2009, "sirolimus, the mTOR kinase inhibitor, sensitizes AML cells, HL-60 cells, to the cytotoxic effect of arabinozide cytarabine."],
        [2019, "Apatinib combined with cytarabine resists AML through synergistically regulating cell cycle and promoting apoptosis."],
        [2011, "Treatment of poor-risk myelodysplastic syndromes and AML with a combination of azacitidine and valproic acid."],
        [1985, "Low-dose cytarabine regimen induced a complete remission with normal karyotypes in a case with hypoplastic AML with No."],
        [1982, "Treatment of relapsed AML with a combination of aclarubicin and cytarabine."],
        [2013, "azacitidine (azacitidine) has changed the outcome of patients with MDS or AML (AML) unfit for intensive chemotherapy."],
        [2001, "Remission induction chemotherapy for AML typically combines cytarabine with an anthracycline or anthracycline derivative."],
        [2017, "Purpose gemtuzumab-ozogamicin (gemtuzumab-ozogamicin), a CD33-targeted immunoconjugate, is a re-emerging therapy for AML (AML)."],
        [2016, "Resistance to cytarabine remains a major challenge in the treatment of AML (AML)."],
        [2004, "The clinical efficacy of arsenictrioxide (As(2)O(3)) has been shown in patients with relapsed AML (APL)."],
        [2001, "These data suggest that cdk2 activity is likely to play a role in cytarabine-induced apoptosis in AML cells."],
        [2010, "Cytarabine is a chemotherapeutic agent predominately used for the treatment of AML and lymphoblastic leukemia."],
        [2012, "Valproic acid combined with cytarabine in elderly patients with AML has in vitro but limited clinical activity."],
        [1999, "Recently, arsenictrioxide (As) was shown to be an effective treatment of AML (APL)."],
        [2014, "Limited data are available on azacitidine (azacitidine) treatment and its prognostic factors in AML (AML)."],
        [2000, "A novel therapeutic potential for AML using arsenictrioxide (As(2) O(3) ) has been reported."],
        [2018, "The 2 main formulations of anthracycline used for AML (AML) induction therapy are idarubicin (IDA) and daunorubicin."],
    ]
    
    #df = pd.read_csv('https://docs.google.com/spreadsheets/d/' + '1A-O505D_vkOprtWKMyQ1hIgNlaLwwBZnIZukiiVTncQ' + '/export?gid=0&format=csv', sep=',', escapechar='\\')
    
    return pd.DataFrame(data, columns=['filename', 'sentences'])

def flat_list(composed_list):
    if any(isinstance(x, list) for x in composed_list):
        composed_list = [item for sublist in composed_list for item in sublist]

    return composed_list

# MAIN PROGRAM:
if __name__ == '__main__':
    if 'execution_counter' not in st.session_state:
        st.session_state['execution_counter'] = 0
        
    sentences_df = get_sentences_dataset()
        
    hide_streamlit_style = """
            <style>           
            footer {
                visibility: hidden;
            }
            
            footer:after {
                content:'Developed by Matheus Vargas Volpon Berto.'; 
                visibility: visible;
                display: block;
                position: relative;
                padding: 5px;
                top: 2px;
                color: black;
            }
            </style>
            """
    st.markdown(hide_streamlit_style, unsafe_allow_html=True)
    
    with st.sidebar.form('sidebar_form'):
        st.header('Models exploration settings')
        
        loaded_model = st.selectbox(
         'Choose one of the preloaded models:',
         ('19: 1921 - 2022',
          '18: 1921 - 2018',
          '17: 1921 - 2014',
          '16: 1921 - 2013',
          '15: 1921 - 2011',
          '14: 1921 - 2009',
          '13: 1921 - 2001',
          '12: 1921 - 1999',
          '11: 1921 - 1998',
          '10: 1921 - 1995',
          '09: 1921 - 1983',
          '08: 1921 - 1982',
          '07: 1921 - 1977',
          '06: 1921 - 1976',
          '05: 1921 - 1974',
          '04: 1921 - 1971',
          '03: 1921 - 1969',
          '02: 1921 - 1967',
          '01: 1921 - 1963'))
        
        top_n = st.slider('Select the neighborhood size',
            5, 20, (5), 5)
        
        input_sentence = st.text_input(label='Input sentence', max_chars=128, help='Type the sentence that you want to compare to the others.')
        
        submitted = st.form_submit_button('Apply settings')
    
    st.sidebar.header('GitHub Repository')
    st.sidebar.markdown("[![Foo](https://cdn-icons-png.flaticon.com/32/25/25231.png)](https://github.com/matheusvvb-19/WE4LKD-leukemia_w2v)")
        
    st.title('Sentence Viewer')
    st.header('Sentence Embedding Visualization Based on Cosine Similarity')
    with st.expander('How to use this app'):
        st.markdown('**Sidebar**')
        st.markdown('Select the BERT-based model that you want to explore. Then, define the number of most similar sentences from the dataset that you want to compare to your input sentence. Finally, type your input sentence in the text box and click on "Apply settings"')

        st.markdown('**Main window**')
        st.markdown('_Hint: To see this window content better, you can minimize the sidebar._')
        st.markdown('lalala')
        
    if submitted or st.session_state['execution_counter'] != 0:
        st.markdown('**Input**')
        st.markdown(input_sentence)
        
        st.session_state['execution_counter'] += 1

        aux_df = sentences_df[(sentences_df["filename"].values <= int(loaded_model[-4:]))]
        sentences = aux_df['sentences'].to_list()
        sentences.insert(0, input_sentence)

        tokenizer = AutoTokenizer.from_pretrained('microsoft/BiomedNLP-PubMedBERT-base-uncased-abstract-fulltext')
        model = AutoModel.from_pretrained('matheusvolpon/WE4LKD_AML_distilbert_1921_{}'.format(loaded_model[-4:]))

        # initialize dictionary that will contain tokenized sentences
        tokens = {'input_ids': [], 'attention_mask': []}

        for sentence in sentences:
            # tokenize sentence and append to dictionary lists
            new_tokens = tokenizer.encode_plus(sentence, max_length=128, truncation=True,
                                               padding='max_length', return_tensors='pt')
            tokens['input_ids'].append(new_tokens['input_ids'][0])
            tokens['attention_mask'].append(new_tokens['attention_mask'][0])

        # reformat list of tensors into single tensor
        tokens['input_ids'] = torch.stack(tokens['input_ids'])
        tokens['attention_mask'] = torch.stack(tokens['attention_mask'])

        outputs = model(**tokens)

        embeddings = outputs.last_hidden_state

        attention_mask = tokens['attention_mask']

        mask = attention_mask.unsqueeze(-1).expand(embeddings.size()).float()

        masked_embeddings = embeddings * mask
        summed = torch.sum(masked_embeddings, 1)
        summed_mask = torch.clamp(mask.sum(1), min=1e-9)
        mean_pooled = summed / summed_mask

        # convert from PyTorch tensor to numpy array
        mean_pooled = mean_pooled.detach().numpy()

        # calculate
        similarities = flat_list(cosine_similarity([mean_pooled[0]], mean_pooled[1:]).tolist())
        
        data = {
            'sentence': [],
            'similarity': [],
        }

        for s, si in zip(sentences[1:], similarities):
            data['sentence'].append(s)
            data['similarity'].append(si)

        df_similar_sentences = pd.DataFrame(data).sort_values(by=['similarity'], ascending=False)
        
        st.markdown('**Top {} similar sentences to the input**'.format(top_n))
        st.table(df_similar_sentences.head(top_n))
